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( ABSTRACT 
Strict anti-pollution laws have drastically changed how pharmaceutical 
manufacturers operate. Increased environmental awareness has forced 
changes in the way that sustained release pharmaceuticals are manufactured. 
Coatings which were once applied from organic solutions have been 
reformulated into water based polymeric dispersions that, although effective, 
cannot equal the performance of their predecessors. Research has led to 
updated coatings composed of three time tested polymers; cellulose acetate, 
ethylcellulose and methacrylic acid copolymer. Additionally, new coatings 
have been manufactured from custom polymers which provide excellent 
sustained release. Unfortunately, their development has not progressed 
beyond the laboratory since regulatory bodies worldwide are reluctant to 
approve new polymers for use in vivo. Clearly there exists a need for new 
coating materials that are "environmentally friendly, " approvable for in vivo use, 
and effective. An attempt was made to identify materials which, in addition to 
imparting sustained release, could be used safely, without organic solvents. 
The crosslinking of a water soluble polymer was decided to be the most feasible 
means of achieving that goal. Hence hydroxyethylcellulose (HEC), a water 
soluble, GRAS (generally recognized as safe) polymer was identified and 
evaluated under various conditions. The ability to insolubilize films of HEC was 
demonstrated when films containing riboflavin-5'-phosphate were exposed to 
visible or ultraviolet light. The drug release controlling potential of those films 
was demonstrated by their application to tablets containing model drugs, and 
their subsequent insolubilization via visible light exposure. Release rates of 
tablets with crosslinked coatings were determined in vitro and found to be 
nearly zero order and well controlled, in both water and 0.1 N HCI. The 
( 
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shortcomings of this technique lie in the difficulties in quantitatively assaying 
the crossl inked polymer. Since the crosslinked polymer is largely water and 
organo-insoluble, attempts were made to differentiate between crosslinked and 
uncrosslinked polymer. To date none of the techniques evaluated provides a 
means to differentiate between the HEC's. While analysis of the crosslinked 
polymer has proven difficult, a system capable of providing for the sustained 
release, composed entirely of GRAS materials and not requiring organic 
solvents, has been realized. 
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PREFACE 
This work has been prepared in accordance with the manuscript format 
option for dissertation preparation, as outlined in section 11-3 of The Graduate 
Manual of the University of Rhode Island. Contained within is a body of work 
divided in to three sections. 
Included within Section I is Manuscript 1, a historical review, which 
provides the reader with an introduction to the subject of this dissertation, a 
statement of the hypothesis tested herein, and the specific objectives of my 
research. 
Section II is comprised of three manuscripts, contain the findings of the 
research which comprises this dissertation. These three manuscripts, as well 
as the one found in Section I are presented in the format required by the journal 
to which they will , or have been, submitted. Also included in Section II is a 
compilation of the primary conclusions drawn from this research. 
Section Ill contains three appendices containing, ancillary data 
(information essential to, but not usually included in published manuscripts) and 
other details pertinent to the understanding of the concepts presented in 
Section II. Note that within the graphical representations of data presented in 
this dissertation there may be "f' shaped error bars which depict the standard 
deviation of that data from it's respective mean. This dissertation closes with a 
complete listing of all the works cited in this dissertation, arranged in 
alphabetically by the author's last name. 
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SECTION I 
Manuscript I ''The Sustained Release Coating of Solid Dosage 
Forms: A Historical Review." A general introduction to this research. 
A statement of the hypothesis tested in this dissertation. 
A compilation of the specific objectives of this research. 
Manuscript I 
THE SUSTAINED RELEASE COATING OF SOLID DOSAGE FORMS: 
A HISTORICAL REVIEW 
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THE SUSTAINED RELEASE COATING OF SOLID DOSAGE FORMS: 
A HISTORICAL REVIEW 
ABSTRACT 
The continued development of sustained release technology over the past 
forty years has provided countless ways of producing long acting dosage forms. 
Of all the methods proposed, coating has proven to be one of the most enduring. 
Although many have attempted to introduce new sustained release coatings to 
the marketplace, only three have been widely accepted. This paper seeks to 
provide the reader with a historical review of sustained release coating and 
examine the reasons why three materials, cellulose acetate, ethylcellulose and 
methacrylic acid copolymer have dominated this technology. 
3 
INTRODUCTION 
The coating of tablets, granules, and other dosage forms has provided 
manufacturers with a means to extend the utility of an active ingredient which 
may have physical or biopharmaceutical shortcomings. Usually, great changes 
in the in vivo performance of a problematic, yet effective drug can be imparted 
by applying the proper coating to it. Some of these changes, hiding an 
unpleasant odor for example, may seem insignificant when looked at from a 
biopharmaceutical standpoint. However, it is rather easy to comprehend the 
benefits of applying a thin, acid resistant coating to protect an acid labile drug 
from the low pH of the stomach. 
Several authors (1 ,2,3) have published reviews of pharmaceutical 
coating which pay close attention to the techniques and equipment employed 
for solid dosage forms. These reviews are an invaluable tool to the formulator 
as they contain in depth descriptions of the most common coating processes, 
including individual advantages and disadvantages. An added benefit to these 
reviews is their near timelessness. While it is true that the science of coating 
has evolved over the years, it is also true that the coating equipment which we 
employ today is not much different than that which was used twenty or even 
forty years ago. 
The evolution of coating equipment has not proceeded rapidly, largely 
due to the limited ways in which large amounts of material can be handled 
efficiently. A sim ilar evolutionary trend is evident for coating materials. 
4 
( Although progresses in polymer chemistry have allowed the development of 
specialized polymer systems which provide any number of desired properties, 
the conservative nature of the pharmaceutical industry has, until recently , 
allowed for the widespread usage of only a few. Yet the introduction and 
popularity of these engineered materials is largely responsible for transforming 
pharmaceutical coating from an artform, guarded by a few skilled individuals, to 
a science which can be readily duplicated, tailored to specific needs and 
transferred between manufacturing sites. 
Many contemporary sustained release coatings are really the direct 
descendants of those that were first introduced in the 1950's. While many 
attempts have been made to introduce new coatings to the industry, those 
systems which applied new technologies to extant polymers have proven most 
successful. This paper seeks to provide the reader with a concise overview of 
the coatings employed for sustained release, providing a brief history of the 
most popular coating techniques, an examination of the reasons why products 
are coated, and provide a historical review of sustained release coatings in the 
pharmaceutical industry. 
REASONS FOR COATING SOLID DOSAGE FORMS 
To the layman, tablet coatings may appear as mere decoration added to 
make tablets more attractive to the eye and pleasing to the palate. However, 
just as the sugar coating on some chocolate candies keeps the chocolate from 
melting in your hand, coatings on tablets provide a means to improve the 
stability and performance of the drugs held within them. Of course coatings are 
5 
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not just a cosmetic placed on tablets to make them more inviting, although they 
may be used as such. Sometimes an opaque coating is used to mask a mottled 
or discolored tablet but, more frequently , coatings are used to modify the 
biopharmaceutical properties of a drug or to compensate for physico-chemical 
shortcomings which it may possess. 
It is possible to remedy certain problems encountered in tabletting by 
applying some type of coating. The nature of the problem is what ultimately 
determines which type of coating is applied. Therefore, coatings can be loosely 
placed into one of three categories, grouped by the shortcomings which they 
are intended to overcome. There are coatings which can alter the 
biopharmaceutical profile of a drug and others which help counteract the 
physical incompatibilities of some drugs. Lastly, there are coatings which are 
used for purely cosmetic purposes. 
Many authors have posed many reasons for coating tablets. The 
remainder of this section shall present those reasons which are still relevant 
today and some others which are of historical interest. 
Tablets and other solid dosage forms may be coated to: 
Mask unpleasant tastes and odors 
Hide mottled or discolored tablet surfaces 
Prevent freshly prepared pills and troches from adhering to one another (4) 
Protect from gastric fluids those drugs which are destroyed by acid 
i.e. erythromycin (5) 
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Prevent nausea , vomiting, or ulceration due to irritation (6) 
Impart a delayed action component for repeat action tablets (4) 
Protect a drug from oxygen, carbon dioxide, water, and light (5) 
Prevent incompatibilities between medicaments in a combination tablet (6) 
Provide a semipermeable membrane which limits the release of a drug from 
it's respective dosage form 
TABLET COATING: A HISTORICAL PERSPECTIVE 
Modern coating can be traced to rather humble origins in the kitchens of 
19th century confectioners who had perfected the "art" of pan coating ( 4 ). In 
the confectioner's kitchen, methods were developed to cover sticky, sweet 
candies with a bright layer of colored, sometimes flavored sugar, thus rendering 
them non-sticking, easily transportable, and as pleasing to the eye as they are 
to the palate. One might speculate that pharmacists, often faced with 
preparations that were difficult to handle, would welcome such a novel and 
useful tool to their trade. Unfortunately, during most of the 19th century, nearly 
all prescriptions were prepared by extemporaneous compounding. A 
considerable amount of the pharmacist's time was spent preparing the 
individual prescription so little could be devoted to a process as time consuming 
as sugar coating. In fact, when necessary, most pill coating was performed by 
simple techniques which provided a suitable means of keeping the pills from 
sticking together or hiding their bad taste. Large batches of pills (and later, 
tablets) were uncommon. 
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However, the 19th century pharmacist did find it necessary to apply 
some sort of coating to many of his products especially massed pills, troches, 
lozenges, and tablets. The methods employed may seem quite primitive today, 
but were an effective means of resolving some problems and had the 
advantage of being easy and efficient to use with small amounts of material. 
Perhaps the simplest of these coating methods was the application of a 
small amount of finely divided chalk or confectioner's sugar to the moistened 
surface of pills (4). This was accomplished with two pilling tiles, one sprinkled 
with finely divided dusting powder, the other with a thin layer of gum arabic or 
tragacanth mucilage through which the pills could be continually rolled until a 
thin white coating was obtained. Color could be added by incorporating a small 
amount of dye into the dusting powder. A variation of this method suggests that 
the pills be moistened with an etherial solution of tolu balsam. The principle 
advantage to this variation is that the pills would dry much more quickly due to 
the rapid evaporation of the ether (4). Yet another adaptation of "dusting" was 
Furley's process, which was quite popular in 19th century England. The 
principal difference between the two was the ingredients of the coating. 
Tragacanth and sugar were used in place of dusting powder as the solid portion 
while albumen, obtained from a fresh egg replaced gum arabic as the binder. 
Other coating methods employed at the time varied in complexity ranging from 
the simple (i.e. "gilding") to more complex methods including gelatin and sugar 
coating . In most cases "complexity" meant the need for specialized equipment. 
Of all the early coating methods "gilding" has been subject to the most 
scrutiny. Today it seems somewhat absurd to cover a medicament with a metal 
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which could severely retard or completely prevent it's release in invivo. 
However, at the time it was one of the most elegant and readily available 
methods to coat small quantities of pills. Another advantage to this method is 
the excellent compatibility of gold with other chemicals. Detailed instructions for 
gilding pills are published in many of the earlier all inclusive pharmaceutical 
texts. Parrishes, 4th ed. 187 4, describes several methods for gilding and 
cautions the pharmacist to use only pure gold and limit the amount applied. A 
point of interest in this nearly 120 year old work is the concern about dosage 
form 's "solubility" (a reference to bioavailability). It states 'The former belief that 
a coating with metallic leaf, if sufficient to hide the taste and smell of the pills, 
would interfere with their solubility, has been very much modified by recent 
experience" (4). Indicating, if only on the most rudimentary level, that pills 
coated with gold leaf could effectively release their medication in the 
gastrointestinal tract. 
While successful in their own right, "dusting" and "gilding" were gradually 
replaced by "dipping" and pan coating. Dipping, a process once nearly 
forgotten, but recently resurrected in a refined form for several OTC 
preparations (Tylenol Gelcaps) , is mentioned briefly in Parrishes and is 
discussed at great length in Remington's 3rd ed. 1894 (7). Similar coverage of 
sugar coating a technique whose popularity was ever growing at the turn of the 
century, can also be found in these works. 
Generally, pills were dip coated in one of three materials gelatin, keratin 
and salol. Of these three, gelatin was the most popular and versatile, while 
keratin and salol were reserved for enteric coatings (8). This fairly simple and 
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effective process for coating involved the placement of freshly prepared pills 
onto Jong pins which were then dipped, several times, into a hot solution of 
gelatin. After hardening, the pins were removed and the hole which they left 
behind was filled with additional gelatin. This efficient process was well suited 
for the extemporaneous compounding of pills and many machines which 
improved the process were patented. 
"Dip Coating" of pills was quite effective, regardless of the few 
shortcomings of the method, however it was impossible to coat compressed 
tablets in this manner because they could not be easily pierced with a needle. 
A remedy to this problem and a better way to coat pills was invented by J.B. 
Russell and later adopted by Parke, Davis & Co (7). This apparatus replaced 
the pins, previously used to hold pills, with a suction device which covered one 
half of the tablet. Tablets were still dipped in the gelatin solution and allowed to 
cool. Once cool , another set of tubes with vacuum was applied to the opposite 
side of the tablet while the first set was removed. Again the tablets were dipped 
and allowed to cool. The result was a gelatin coated tablet or pill that did not 
require further processing. 
As the turn of the century approached, sugar coating in rotating pans 
was becoming the coating standard in large pharmaceutical houses. Jn a large 
company, product batches were of sufficient size to warrant the use of pan 
coating. Many thousand pills or tablets could be economically coated by 
relatively few employees. The era of modern pharmaceutical coating had 
begun. 
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During the first half of this century, tablet coating evolved into the 
processes with which we are familiar today. Sugar coating pans have changed 
little in the last one hundred years. Copper pans, a leftover from confections, 
have been replaced by stainless steel. The source of drying air has progressed 
from charcoal fires (4) to steam and finally, the forced hot air systems in use 
today. Lastly, the coaler's ladle has been replaced by a spray nozzle to better 
control the application of coating solutions. 
While the art of sugar coating had reached near perfection in the early 
1950's its shortcomings (9) would lead to its overshadowing by a more efficient 
and versatile technology. The introduction of film coating (Abbott Laboratories, 
1953) to the pharmaceutical industry allowed for great changes in the way 
formulators perceived tablets. No longer were they bound to the use of 
featureless, nearly spherical tablets as the newer polymeric coatings allowed for 
tablets of many shapes. Even embossed tablets could be coated in an efficient 
and aesthetically pleasing manner. These new coatings although versatile, 
were not well suited for use in existing coating equipment. At about the same 
time as the development of the new polymeric coatings, two advances in 
coating technology were introduced. Both of which have become essential to 
the modern pharmaceutical industry. 
The addition of many small holes and it's enclosure within a sealed 
cabinet were modifications of the conventional coating pan which led to the 
"perforated" pan. Perforated pans (i .e. Thomas Engineering's Accela Coater 
and others) allow for the passage of great volumes of air across the tablet bed 
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and controlled temperatures which are necessary to meet the demands of 
polymeric film coatings. 
The second of these innovations, the air suspension coater was an 
entirely different approach to coating (10). Unlike coating pans, the mechanics 
of the suspension coater caused tablets to continually rise and fall in a stream 
of gas while the coating solution is sprayed onto them from below. Since it's 
inception, the "fluid bed" coater has undergone continual modification leading to 
a very versatile tool capable of coating tablets, pellets, and even very small 
granules in a timely fashion. While capable of many things, perhaps the 
greatest advantage of this apparatus lies in its ability to function in a "closed 
loop" thereby facilitating the recovery of organic solvents and increasing the 
level of occupational and environmental safety. 
Further advances in coating technology have been less monumental yet 
have served to enhance the existing technology. After all , the coating 
machinery and methods most commonly employed are well suited to the types 
of coating that is performed in today's industry. Likewise, progress in coating 
machinery will most likely accompany, or follow, the development of new types 
of coatings. Unfortunately, this is the age of cost containment and conservative 
formulation strategies within the industry. The chance of an entirely new 
approach to tablet coating coming into large scale usage in the near future is 
rather small unless it proves vastly superior to existing methods. 
SUSTAINED RELEASE COATINGS: A HISTORICAL SURVEY 
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In the preceding section , an attempt was made to provide the reader with 
an overview of the methods and technologies employed in the coating of solid 
dosage forms during the past century. The majority of the methods described 
were simple, developed by pharmacists for use within the pharmacy, primarily 
for the purpose of making distasteful drugs more palatable. Later, coating 
would evolve into a science which allowed the formulator to selectively alter, or 
improve, the biopharmaceutical behavior of the products to which they were 
applied. 
Although there are many ways to obtain the sustained release of 
medication (11 , 12), coatings applied to tablets, pellets, or granules are perhaps 
the most popular. According to USP XXll (13) there are three classes of 
coating commonly employed in the manufacture of solid dosage forms. The 
oldest of these, the "Plain Coatings" (USP XXll) , are those used to alter the 
taste and appearance of tablets or to protect them from the detrimental effects 
light and moisture. Plain coatings, perhaps best exemplified by sugar and 
hydroxypropylmethylcellulose, are not intended to alter the biopharmaceutical 
performance of the drug contained within them. The second group of coatings, 
dubbed "Delayed Release" by USP, are more commonly known as "enteric". 
The enteric coatings (i.e. cellulose acetate phthalate), due to their poor solubility 
in acidic media, serve to protect acid labile drugs from the low pH of the 
stomach by delaying their release until the tablet has reached the intestinal 
tract. Sustained release coatings ("extended-release" USP XXll) , those which 
have been designed to meter the amount of drug released from a dosage form , 
complete the list. 
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Until this point, the discussion of sustained release film coatings has 
been oversimplified, implying that the coating is a single, pure entity. Rather, 
film coatings are a mixture of several components which result in a continuous 
film with desirable properties. Generally, a film coating solution will contain four 
basic components; film former, solvent, plasticizer, and colorant (3). These 
components, both alone and in conjunction with one another have been the 
subject of numerous studies and several lengthy reviews. While not the focus 
of this paper, general reviews of film coating have been presented by Banker 
(14), Conrad and Robinson (15), and Seitz et al. (1 ). 
Pharmaceutical film coatings is a broad terminology which encompasses 
several types of film . These films modify the release of medicaments via three 
basic mechanisms; erosion (polyethylene glycol}, gel formation 
(hydroxyethylcellulose) and diffusion (ethylcellulose). Those coatings which 
provide release through diffusion have a reputation of being predictable, easy to 
apply and are probably the most common sustained release coatings employed 
today. Yet the majority of today's sustained release coatings are ones, or 
descendants of ones, first used in the 1950's. Generally, the evolutionary path 
of these coatings began with polymers dissolved in organic solvents. Later, in 
response to many factors , attempts were made to prepare entirely or partially 
aqueous coating solutions. Throughout the past forty years other coating 
techniques have also been attempted, none of which has received the 
acceptance of coating from solution. 
The vast body of literature published on the subject of coating would lead 
an investigator to believe that there are hundreds of coatings and 
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methodologies employed today. A closer examination reveals the contrary. 
The current United States Pharmacopeia only lists three sustained release 
coatings that function as a rate controlling membrane; cellulose acetate, 
ethylcellulose, and methacryl ic acid copolymer. Although other coatings exist, 
these three remain the most popular, undergoing continual modification to 
withstand the challenges of time and changing regulatory climates. As the 
previous sentence suggests, the evolution of sustained release coatings was 
not one that was purely driven by the quest for better performance. Other 
issues, including safety (occupational and environmental) and cost have played 
an equally important role in the development of suitable coatings. 
At the time film coating was introduced to the marketplace (Abbott 
Laboratories 1953) researchers were searching for economical and more 
versatile alternatives to sugar coating (9). The use of polymeric film formers in 
conjunction with organic solvents was perhaps the most important advance in 
dosage form development of that era. Their introduction provided researchers 
with new avenues to explore in the quest for controlled drug delivery and has 
led to the invention of many of the technologies which are so important today. 
Many of the early commentaries touted the benefits of organo-soluble 
polymers as coating agents while they remained quite apprehensive about the 
use of aqueous solutions (9, 17). The fear of dilute aqueous solutions was 
largely based on experience gained from sugar coating where the high water 
contents of coating solutions were implicated as the cause of stability problems 
and long processing times. The principle benefits of solvent usage were the 
considerable reduction in processing times and the removal of water from the 
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process, thereby reducing the loss of active ingredient through hydrolysis. Yet 
another advantage of organic solvents was their ability to completely dissolve 
the polymeric film formers thereby allowing for smooth, continuous coatings 
which were capable of protecting medicaments from environmental stresses 
and making tablets more distinctive. 
An early patent for a sustained release tablet is recognized as the first to 
make use of a polymeric membrane to control the release rate of a drug 
substance. Assigned to Consolazio in 1949 (US patent # 2,478, 182), this 
patent described the manufacture of a tablet composed of granules of sodium 
chloride coated with cellulose acetate or cellulose nitrate that was designed to 
eliminate the gastrointestinal upset caused by the localized deposition of 
medicaments.. Consolazio claimed that the invention delayed the solution time 
of sodium chloride some 60 to 80 minutes by the gradual leaching of drug 
through and the subsequent bursting of the cellulosic membrane (11 ). 
Unbeknownst to Consolazio at the time, was the semipermeable nature of 
cellulose acetate. His results might have been quite different if a larger organic 
molecule had been used since, due to their size, many drugs will not pass 
through cellulose acetate membranes. Although larger organic molecules are 
retained, water will still enter the tablet leading to the eventual bursting of the 
membrane and subsequent "dumping" of the medication within. A similar 
approach to sustained release was undertaken by Rosenthal (US patent # 
2,895,880 issued 1959) that substituted any one of a number of prolamines for 
cellulose acetate. The principal difference between this approach and that of 
Consolazio was the digestibility of prolamines which would ensure the release 
of medication into the GI tract. 
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By 1958 ethylcellulose had joined cellulose acetate as a polymeric 
membrane for sustained release. A patent issued to Lowey (US patent 
2,853,420) made use of granules of an inert material that were coated with a 
solution of ethylcellulose and drug. Once ingested, the drug entrapped within 
the ethylcellulose membrane would slowly diffuse out from the membrane and 
be absorbed. Knowledge of the mechanics of diffusion allowed the release rate 
to be "programmed" by blending together granules of differing film thicknesses. 
It is interesting to note that the three polymers most commonly used 
today as sustained release membranes were introduced to the industry before 
1962. Cellulose acetate and ethylcellulose, both mentioned previously, were 
introduced before 1958. The third polymer (really a class of polymers) 
Methacrylic acid copolymer, was first used in a 1961 matrix formulation 
patented by Levesques (US patent# 2,987,445). Levesques designed a matrix 
tablet which contained drug and soluble pore formers dispersed in a matrix of 
polyethylmethylmethacrylate or copolymers of methylmethacrylate and 
alkylacrylate that allowed for the slow leaching of drug into the gastrointestinal 
tract. 
The fact that only three polymers which provide sustained release 
through membrane diffusion are listed in USP should not be construed as a lack 
of research in this area. Several researchers of the 1960's sought to find other 
polymeric materials that would exhibit suitable sustained release properties (18, 
19, 20, 21 ). Much of their work was focused on various combinations of other 
vinyl , acrylic, and cellulosic polymers and provided a battery of screening tests 
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by which the suitability of a candidate polymer system could be judged. 
However, what these studies had failed to do was develop a new organo-
soluble coating system which would be widely accepted by the industry. 
Possible reasons for this are many but perhaps the two most significant ones 
are the risks associated with organic solvent usage and the emergence of a 
newer hybrid technology, the pseudolatex coating. 
Near the end of sixties, new, improved methacraylate derivatives had 
been introduced to the industry for use as diffusion controlled membranes (22). 
Although they performed well , these copolymer systems represented the end of 
an evolutionary pathway. Stricter environmental legislation in conjunction with 
the high cost of controlling organic solvent emissions forced researchers to find 
alternative, "environmentally friendly" coating systems. An early, and now 
widely known, product of this search was the pseudolatex dispersion. 
Research has shown that pseudolatex dispersions, finely divided 
colloidal dispersions of water insoluble polymers in aqueous media, can be 
prepared from many water insoluble polymers. These preparations possess 
several properties which made them the most popular possible replacements 
for organic solvent based coatings including; no need for organic solvents, high 
solids concentration with low viscosity, shorter drying times through increased 
solids concentration, and lower water vapor permeability than comparable films 
from organic solution (23). 
The use of latex dispersions invivo could be traced back to their listing in 
the U.S. Federal Register (1961) as a food additive (23). Later, after perfecting 
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acrylate pseudolatexes for other pharmaceutical coatings, at least two 
researchers had developed systems which would provide diffusion controlled 
drug release (24, 25). The commercial acceptance of acrylate pseudolatexes 
for diffusion controlled membranes (Eudragit (26)) led to the development of 
ethylcellulose pseudolatexes (Aquacoat (27) and Surelease (28)) and more 
recently , those made form cellulose acetate (FMC corporation (27)) . 
Pseudolatex technology has received such considerable attention from 
both academic and industrial researchers that an in depth discussion would be 
redundant and beyond the scope of this paper. If interested in the science and 
application of these coatings the reader should start by consulting the chapters 
by Lehman and Steurnagel in Aqueous Polymeric Coatings for Pharmaceutical 
Dosage Forms (22,23) as they provide comprehensive reviews of the subject. 
While the pseudolatex coatings mentioned previously have been proven 
effective in many pharmaceutical applications, one somewhat disturbing fact 
remains. The extensive research on, and the wide acceptance of this 
technology is a largely due to the fact that the same three, well accepted 
polymers which had been historically used for sustained release were used in a 
new manner. In fact, it is only recently that another, completely different 
polymer has begun to gain acceptance. In 1989 Li and Peck (29) introduced 
sustained release tablets that were coated with a silicone elastomer latex (Dow 
Chemical (30)) . Although it was yet another latex type coating, the use of a 
silicone elastomer represented a departure from the use of methacrylate and 
cellulosic polymers. 
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Unlike the existing latexes, those made of silicone are completely 
impermeable to water and require the use of a pore forming agent, usually 
polyethylene glycol, and an anti-tack agent, fumed silica. The amount of 
polyethylene glycol in the film ultimately determines its porosity and subsequent 
drug release rate. Li and Peck demonstrated the ability of silicone elastomers 
to provide the apparent zero order release of potassium chloride from coated 
tablets for greater than 12 hours with 20 percent PEG 8000 (29). Faster 
release could be gained by increasing the percentage of PEG. Other factors 
which were believed to have an effect on the release rate from silicone 
elastomer films include; the weight of coating applied, heat treatment and pH of 
the dissolution media have been confirmed by Dahl and Sue (31) 
The silicone elastomer latex represents an adaptation of existing 
pharmaceutical technology to a new type of polymer. Although not yet 
approved for use in pharmaceutical formulations, silicone elastomers are used 
for medical applications and are a representative of a trend which has 
developed within the industry. The manufacturers of pharmaceutical excipients 
are well aware of the difficulties that are encountered when new excipients are 
submitted for FDA approval. The fact that only three polymers that provide 
diffusion controlled sustained release are listed in the Pharmacopeia is due, not 
to a lack of research, but due to the difficulty with which a prospective polymer 
would gain approval. It seems that contemporary research has taken this into 
consideration and has focussed it's effort on materials which are already 
approved for invivo usage. 
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on yet another major trend in pharmaceutical coating. Remember that 
sustained release coatings began as organic solutions and evolved to aqueous 
dispersions in response to changing safety and environmental regulations. 
Much of the sustained release film research during the 60's and ?O's was 
centered on updating the polymers which had been used previously with a few 
noteworthy exceptions. 
One of these attempts was is described in a patent issued to Seiyaku in 
1967 (British patent #1 ,075,404) which described the "electrostatic" coating of 
tablets. In its truest form , electrostatic coating allows for the deposition of thin 
polymeric films without the need for any solvent. Films are formed when a 
charged particle is attracted to a substrate of opposite charge. Seiyaku's 
invention was not really a true electrostatic coating as it still required the use of 
a solvent which had to be removed after coating (32). Another earlier attempt 
by Endicott and later marketed by Abbott as "Gradumet" is a forerunner of some 
of the more interesting attempts of recent years (11 ). The Gradumet was a 
matrix tablet composed of drug and a plastic carrier which, after manufacture, 
was exposed to acetone vapors causing a the plastic to coalesce into a 
continuous network. The coalesced plastic provided a tortuous matrix which 
delayed the release of the drug held within it. 
Recent studies of sustained release coatings appear to be branching out 
onto two pathways. While some determined researchers are experimenting 
with polymeric materials which have not yet gained FDA approval, others are 
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looking at ways to modify other preapproved polymers to provide sustained 
release membranes. 
Perhaps the most promising attempt to make use of an already approved 
polymer lies in the crosslinking of alginic acid salts. The sodium salt of alginic 
acid is a hydrophillic, water soluble polymer which has traditionally been used in 
tablet manufacture as a binder and disintegrant. On the other hand, the 
calcium salt, although hydrophillic, is insoluble in water. Julian and colleagues 
studied the ability of free films of calcium alginate to control the release rate of 
drugs (33). Later, several researchers studied coating methods which 
converted sodium alginate to calcium alginate on the surface of the tablet or 
pellet (34,35). Bhagat et. al. describe a method in which guiafenisen tablets 
containing calcium chloride are dipped into a solution of sodium alginate. 
Immediately after immersion, insoluble calcium alginate begins to form on the 
tablet surface. Throughout the immersion calcium chloride, and unfortunately 
some drug, leach out of the calcium alginate membrane thereby maintaining the 
conversion of polymer at the surface. The thickness of the coating is controlled 
by the time of immersion in the sodium alginate solution. Through the use of 
this method Bhagat was able to produce tablets with an approximate film 
thickness of 2 mm that were able to provide the sustained release of 
guiafenesin for four hours. This technique, although promising, is not without its 
shortcomings. Perhaps the most difficult of these are the Joss of drug during 
film formation and the rather thick films required for reasonable release rates. 
Abletshauser and co-workers, dissatisfied with the immersion method 
used by Bhagat, adapted the sodium to calcium alginate crosslinking process 
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for use in a fluid bed coater (35) . In their study pellets of indomethcin and 
acetaminophen were coated in a specially modified fluid bed that contained two 
spray guns. One gun sprayed a sodium alginate solution, whi le the other 
sprayed calcium chloride in alternating cycles. Drug release from these pellets 
with a 100 micron thick coating was extended over periods of three and eight 
hours for acetaminophen and indomethacin respectively. Although this method 
elim inated the drug loss of Bhagat's technique, it required considerable 
processing times due to the large amount of water in the coating solutions. 
While aqueous coatings have eliminated many of the problems found in 
solvent coating, the removal of water remains a problem. Some recent 
attempts at novel sustained release coating have sought to develop systems 
which do not require any solvent. Yoshida and co-workers reported the 
sustained release of potassium chloride from beads of gamma radiation 
crosslinked methacrylates (36). The production of the beads was accomplished 
by dropping a liquid mixture of drug and monomer into an extremely cold 
quenching bath and then exposing the frozen globules to gamma rays. The 
extent of crosslinking was so complete and impermeable that the addition of 
PEG 600 was necessary to facilitate diffusion. 
A similar approach to coating is currently under study by Wang and 
Bogner who have been experimenting with the photocrosslinking of several 
siloxane prepolymers (37,38). Unlike that of Yoshida, their method employs the 
use of high intensity UV light in conjunction with a suitable photoinitiator 
(Benzoin Methyl Ether) that has been adapted for use in a flu id bed coater. 
With in the coater, the liquid prepolymer and photocatalyst can be sprayed onto 
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pellets and exposed to the UV light. Upon exposure to the UV light the polymer 
will begin to crossl ink, thereby increasing in viscosity until a solid, insoluble 
coating is obtained. 
Radiation crosslinking offers a novel and economical way to produce 
sustained release coatings in the future. Unfortunately, current academic 
research must overcome several problems if it is to be accepted for invivo 
usage in the future. Firstly, both of the radiation crosslinked methods 
mentioned previously make use of prepolymeric monomers which pose serious 
health risks if they remain unpolymerized. Additionally, some of the methods 
require catalysts which may also prove toxic. Still another possible problem lies 
in use of rad iation as an energy source. Remember that ultraviolet light has 
long been known as a cause of drug degradation. Yet, if a system can be 
developed which makes use of materials which are approved, or approvable, for 
invivo usage it will open up many new opportunities for improved 
pharmaceutical coatings. 
CONCLUSIONS 
Coating, in one form or another, remains an integral part of the 
pharmaceutical industry. Yet to fully understand its future, investigators must 
be aware of the vast body of work which precedes them and make use of the 
information contained within it. The past forty years have provided the 
pharmaceutical industry with several lessons which have been, and will remain 
valuable. While it is true that the equipment and materials used in the 
manufacture of coated, sustained release dosage forms has not changed 
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screened for use as release rate controlling membranes yet, until recently only 
three have been widely used. The same three polymers which were once 
deposited from organic solution, have been continually updated to comply with 
ever changing pharmaceutical, safety, and environmental regulations. 
As researchers continue to develop new types of sustained release 
coatings, they must remember that those which have been successful in the 
past have been so, not only due to their performance, but also because of their 
prior approval for invivo usage. Future investigators should not regard this 
observation as a warning to avoid new, unapproved materials. Rather, it should 
serve to impress upon them the realities of the pharmaceutical industry. While 
there have been many good ideas, greater attention should be given to those 
systems which are ultimately approvable. 
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HYPOTHESIS TESTED HEREIN 
It should be possible to develop an entirely water soluble polymeric coating 
system for solid, pharmaceutical dosage forms, which will provide adequate 
dissolution control and have the potential for commercial application, when 
such a system is produced via controlled exposure to radiation. 
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SPECIFIC OBJECTIVES of RESEARCH 
I. Search literature for: 
a. Polymers that may be crosslinkable and have been 
demonstrated to be safe for usage in vivo. 
b. Prior examples of radiation induced crosslinking in 
pharmaceutical preparations. 
II. Evaluate the potential of rad iation induced crosslinking in the 
manufacture of pharmaceutical dosage forms. 
Ill. Explore the nature of radiation induced crosslinking of 
hydroxyethylcellulose under different experimental conditions 
(radiation source, molecular weight of polymer, catalyst 
concentration, etc.). 
IV. Examine the effect of crosslinked films on drug dissolution control. 
V. Explore the possible physico - chemical changes which 
hydroxyethylcellulose may undergo as a result of the crosslinking 
conditions selected. 
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SECTION II 
Manuscript II "Photocrosslinked Hydroxyethylcellulose Membranes as 
Sustained Release Coatings: A Feasibility Study." 
Manuscript Ill "Photocrosslinked Hydroxyethylcellulose Membranes 
as Sustained Release Coatings: Assessment of Performance In 
Vitro." 
Manuscript IV "Photocrosslinked Hydroxyethylcellulose Membranes 
as Sustained Release Coatings: Problems Associated with and 
Possible Solutions for the Characterization of Crosslinked Materials." 
Primary conclusions drawn from this investigation. 
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Manuscript II 
PHOTOCROSSLINKED HYDROXYETHYLCELLULOSE MEMBRANES 
AS SUSTAINED RELEASE COATINGS: A FEASIBILITY STUDY 
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( PHOTOCROSSLINKED HYDROXYETHYLCELLULOSE 
MEMBRANES AS SUSTAINED RELEASE COATINGS: A FEASIBILITY STUDY 
ABSTRACT 
Photocrosslinkable films which provide prolonged drug release have been 
developed as possible alternatives to traditional organo - soluble polymeric 
coatings. Unfortunately, the utility of many of these systems may never be 
realized due to concerns over the in vivo safety of one or more of their 
components. This study explores the feasibility of producing photocrosslinkable 
films that lessen or eliminate safety concerns through the use materials which 
have prior approval for use in pharmaceutical preparations. Through the careful 
selection of polymer and photocatalyst, films have been produced that readily 
crosslink upon exposure to an appropriate light source. Once crosslinked the 
polymer, hydroxyethylcellulose, is no longer readily soluble in aqueous media. 
Possible advantages of this system as a possible pharmaceutical coating, lie in 
the regulatory acceptance of each of its components and its ability to crosslink 
when exposed to visible light. 
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INTRODUCTION 
The introduction of the sustained release (SR) coating to solid dosage 
form manufacture during the 1950's had revolutionized oral drug delivery and 
opened up many new research paths for pharmaceutical scientists. A review of 
the coating literature might lead contemporary formulators to believe that there 
are dozens of different sustained release coatings at their disposal. Closer 
examination reveals that nearly all of the coatings in use today have been 
derived from one of three, time tested polymers (cellulose acetate, 
ethylcellulose, and methacrylic acid copolymer) that have been in use since the 
1950's. 
The reasons why today, some forty years since the introduction of 
sustained release coatings only three polymers have been widely accepted, 
surely cannot be blamed on a lack of research. Since the 1950's, many authors 
have published studies which sought additional polymers that could meet this 
need (1-5). While they were successful in their searches, their candidates were 
nonetheless unacceptable for in vivo use. The failure of so many of those early, 
second generation polymers to gain acceptance by regulatory bodies may be 
summed up by one word, safety. 
The safety of cellulose acetate, ethylcellulose, and methacrylic acid had 
been proven by many years of use prior to the adoption of strict safety 
legislation. Because of increased concerns over product safety, many possible 
successors to the aforementioned polymers did not, nor likely ever would, gain 
such approval. 
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While the concern over safety in vivo remained an important criteria to 
judge possible SR coatings, the heightened environmental awareness of the 
1970's introduced additional criteria which played an equally important role in 
their fate. Prior to the 1970's most SR coatings were applied from organic 
solutions providing for elegant and effective coatings that were both easy and 
economical to apply. Economical, until The Clean Air Act of 1970 and the 
increased awareness of the health risks associated with prolonged organic 
solvent exposure placed restrictions on their use (6). 
During the late 1960's aqueous derivatives of the traditional organic 
solvent coatings were developed with the hope that they might someday 
eliminate the need for the organic solvents (7). Although these pseudolatex 
coatings have proven useful, they too have limitations. Consequently, the 
search for new coatings continues with much of the effort being spent on 
alternate formulations of the same three, time tested polymers. While it makes 
sense to try to modify extant techniques, there are always alternative 
techniques which should be investigated. 
One possible avenue of investigation is the insolubilization of water 
soluble cellulose derivatives with a suitable crosslinking agent (i.e. 
divinylsulphone, dimethylurea and glyoxal) (8-10). The application of such 
technology to pharmaceuticals appears quite feasible at first. However, the 
toxic potential of the crosslinking agents and the harsh conditions required for 
their reaction makes the use of these techniques nearly impossible in 
pharmaceutical manufacturing, unless a less destructive, less toxic system can 
be developed. 
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Uehara and Sakata report that hydroxyethylcellulose (HEC) may be 
rendered insoluble, without the use of an external crosslinker, by exposing the 
polymer to a gas plasma (corona treatment) (11 ). Other researchers have 
reported the insolubilization of cellulose ethers by exposure to ultraviolet light in 
the presence of a photosensitizer (i.e. chrome or azo dyes) (12). While several 
azo dyes are approved as colorants for pharmaceuticals, many are under 
scrutiny by regulatory agencies and their future as pharmaceutical excipients is 
in question. 
This paper seeks to determine the feasibility of producing a purely 
aqueous sustained release coating, containing a polymer and photocatalyst that 
may be deposited, by conventional means, onto the surface of a tablet and 
rendered water insoluble by exposure to light. While others have attempted 
similar radiation crosslinked coatings (13, 14), their methods are such that the 
source of radiation may cause extensive drug degradation or pose serious 
health risks due to the toxicities of the photocatalysts or monomers employed 
(15). 
It should be possible to circumvent the shortcomings of the 
aforementioned radiation cured coatings through the careful selection of coating 
components. The system discussed in this paper has been prepared entirely 
from FDA approved components and employs an insolubilizing technique which 
is less likely to be detrimental to the dosage form . 
MATERIALS AND METHODS 
Materials 
Natrosol 250 L, M, and H pharmaceutical grade hydroxyethylcellulose 
was provided by the Aqualon Corporation (Wilmington, DE). The viscosity 
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(by the manufacturer) to be 90,000, 720,000 and 1,000,000. Riboflavin and 
Riboflavin-5'-phosphate sodium were purchased from Sigma Chemical (St. 
Louis, MO) while FD&C Red #3, FD&C Red #40, FD&C Blue #1 , FD&C Blue #2, 
FD&C Green #3, FD&C Yellow #5 and FD&C Yellow #6 were provided by 
Warner Jenkinson (St. Louis, MO). Methanol, Urea, Acetone, HCI (0.1 N) and 
NaOH (0.1 N) were purchased from Fisher Scientific (Springfield, NJ). 
Simulated Gastric Fluid with enzyme was prepared as per USP XXll. 
Screening of Possible Catalysts 
Hydroxyethylcellulose is readily water soluble when its molecular weight 
is less than 1.3 x 106. Therefore, films prepared for this study were expected to 
be readily soluble unless some degree of crosslinking had occurred . 
For the initial photocatalyst screening studies, aqueous solutions of each 
candidate dye (6 mg/ml) were prepared. A 1.0 ml aliquot of each dye was 
added to 9.0 ml of a 3.0 % Wfw solution of Natrosol 250 L (90,000 mw) and 
mixed thoroughly yielding a final dye concentration of (0.6 mg/ml). A small 
amount of each solution was then poured onto individual glass plates, spread to 
a thickness of 12 mils (0.305 mm) and subsequently dried at 5ooc resulting in a 
film with a 2.0 % dye concentration based on total solids content. 
After drying the films were placed on to a conveyor belt moving at 30 feet 
per minute and exposed to 600 watts of ultraviolet light from two mercury arc 
lamps placed six inches overhead. The amount of UV exposure was controlled 
by limiting the number of times which a sample film was passed under the light 
source at a speed of 2 seconds per pass. Samples were exposed for 0, 3, 6, or 
9 passes. Following UV exposure, equal amounts of exposed and control films 
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( were stripped from their glass substrates and placed into 20 ml of water and 
shaken vigorously. After one hour of mixing, the samples were compared 
amongst one another. A qualitative comparison was used to determine which 
dye produced the most insoluble HEC. 
Determination of Optimum Polymer - Photocatalyst Ratios 
Experimental Design 
In order to determine the optimum combination of polymer, catalyst and 
light exposure, a 2x3x6 full factorial design with three replicates was used. In 
the original design, each of the two different grades of polymer designated M 
and H were to be combined with six concentrations of catalyst (0,2,4,6,8 and 
10% w1w based on weight of polymer) and three levels of ultraviolet light 
exposure (0, 5 and 10 passes under UV lamp at a speed of 2 sec./pass). 
After the preceding study had been completed, further experimentation 
revealed that visible light may, in fact provide a better yield of insoluble material 
than UV light. Consequently, a new study with 2 polymer grades (M and H), 3 
levels of visible light exposure (0, 24 and 120 hours}, 3 levels of catalyst (0, 2, 
and 4% Wlw based on weight of polymer), and three replicates was performed. 
The number of catalyst concentrations had been reduced after studying 
preliminary data from the ultraviolet light study. 
Data from each study was fitted to an analysis of variance model using 
PROC GLM on the SAS statistical software (Release 5.18, SAS Institute Inc., 
Cary, NC). All factors and all possible interactions were considered. 
Preparation of Films 
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Stock solutions of HEC, M & H grade, were prepared by incorporating 9.0 
g of polymer into 542.5 g distilled water with the aid of a homogenizer (Silverson 
L4R UK) run at low speed. After preparation the stock solutions were kept in a 
dark refrigerator and allowed to deaerate. The solutions were prepared so that 
a 90 ml al iquot would yield a final polymer concentration of 1.5 % W/w when 
brought up to a volume of 100ml with one of several riboflavin-5'-phosphate 
solutions. 
To obtain the necessary concentrations of riboflavin-5'-phosphate, a 15 
mg/ml stock solution of the catalyst was prepared and protected from light. 
Aliquots of 0, 2, 4, 6, 8, and 10 ml of the riboflavin-5'-phosphate stock solution 
were then pipetted into 10 ml volumetric flasks and brought to volume with 
distilled water. The diluted riboflavin solutions were then added to the 90 ml 
aliquots of the polymer, thoroughly mixed, and allowed to deaerate in a 
darkened refrigerator. 
Prior to film casting, the solutions were warmed to room temperature and 
divided into three equal portions. The portions were then individually poured 
onto preheated (600C) plates of untreated window glass (4 x 8 inches) and 
spread into thin films with the aid of a film casting table (RK Print-Coat 
Instruments, UK) equipped with a# 8 casting rod. The wet film thickness was 
0.040 inch (1.016 mm). After casting the films were dried in a darkened 6ooc 
oven for 24 hours, removed and then stored in darkness until needed. 
Later, the dried films were exposed to either visible or UV light to initiate 
the "crosslinking" reaction. Films kept in darkness were used as controls 
through the study. Ultraviolet light exposure was provided by a Fusion Systems 
(Rockville, Md) F300-6 electrodeless UV curing system equipped with a 
mercury "H" bulb and a conveyor belt operating at 30 feet per minute. The 
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speed of 2 sec./pass) that the plates were passed under the UV lamp. Visible 
light exposure was accomplished with the aid of a Hotpack environmental 
chamber (model 352642, 600 ft. can., 25°C). Films were exposed to the 
lamps for either one or five days and immediately tested upon removal from the 
chamber. 
Percent Insoluble Determination 
The amount of insoluble material was determined by a method adapted 
from that of Geurden (9). A sample of each film was stripped from the glass 
substrate and accurately weighed (approximately 150 to 250 mg per sample). 
The weighed samples were then placed into 100 ml of distilled water and stirred 
for two hours. After stirring the samples were decanted into a fritted glass 
funnel containing a piece of pre-dried, pre-tared filter paper (Whatman #2) and 
rinsed with 200 mis of distilled water. Excess solvent was removed by vacuum 
filtration and the samples were dried for 24 hours at 65 oc. Samples were 
removed from the oven and immediately weighed. The percentage of insoluble 
HEC was determined by the following equation: (weight of paper & soaked film -
weight of paper)! initial weight of film x 100. Each solvenUfilm combination was 
repeated in triplicate. 
Solubility Evaluation 
The solubilities of control and visible light exposed films were evaluated 
in several different solvents in an attempt to understand the changes, if any, 
that the HEC molecule undergoes as a result of the insolubilizing procedure. 
Additionally, several of the test solvents were chosen so that a prediction could 
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be made as to how the crosslinked films would withstand the rigors of the 
gastrointestinal tract. 
Films were prepared from a solution containing 1.5 % W/w 
hydroxyethylcellulose, 0.03 % W/w Riboflavin-5'-phosphate, and 98.47 % 
distilled water which was prepared in a manner that was consistent with 
previous film casting solutions. The solution was then stored in a dark 
refrigerator until needed. 
Films were cast in a manner that was consistent with the procedure 
mentioned previously. Immediately after casting, the wet films were transferred 
to a dark oven and dried, overnight at 55oc. Once dry, the films were divided 
into two groups, one kept in darkness and the other in a lighted stability cabinet 
(Forma Scientific model 3890, 1000 ft. can., 250C) for seven days. 
Afterwards, 2.5 x 4.0 cm pieces of each of the films were cut with a razor 
blade, removed from the glass plates and accurately weighed (approximately 50 
mg/piece). After weighing, the film samples were transferred to an erhlenmeyer 
flask containing 100 m L of either of the following solvents; distilled water, 0.1 N 
HCI, 0.1N NaOH, Acetone, Urea (10 % aqueous), Methanol and Simulated 
Gastric Fluid with Enzyme USP. The flasks were immediately sealed and 
shaken gently for 24 hours. Later, the samples were decanted into a fritted 
glass funnel containing a piece of pre-dried, pre-tared filter paper (Whatman #2) 
and dried for an additional 24 hours. Once dry, the remaining film and filter 
paper were quickly weighed. The percent of insoluble film was determined by 
the following equation; (weight of paper & soaked film - weight of paper)/ initial 
weight of film x 100. Each solvenUfilm combination was repeated in triplicate. 
Microscopic Analysis of Film Samples 
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Microscopic analysis was used to determine if any gross physical 
changes to the surfaces of the HEC films were evident as a result of the UV or 
visible light exposure, as surface changes may be indicative of destruction of 
the film components. Scanning electron microscopy was used to examine the 
surfaces of film samples before and after exposure to UV and visible light 
sources (Leica (Cambridge) Stereoscan S-360). Samples were prepared for 
study by mounting them onto aluminum SEM stubs with double faced tape and 
sputter coating them with gold (Poloron E5100, 1 min. @ 25 Kv). 
RESULTS and DISCUSSION 
Screening of possible catalysts 
Those films which had not been subjected to UV light behaved as 
expected, dissolving quickly and completely when immersed in water. A simple 
physical mixture of polymer and dye did appear to decrease the solubility of the 
polymer. However, upon exposure to UV light, each of the dye I polymer 
combinations produced some amount of insoluble HEC although the amount 
was not quantified. Additionally, small amounts of insoluble polymer were 
obtained from neat films of HEC which had been exposed to UV light. It is 
unlikely however, that these particles were formed through crosslinking rather 
their insolubility is more likely a result of UV induced degradation of the 
cellulose molecules (16). 
Preliminary observation of films which had been immersed in water 
proved discouraging as the films, once wet, rapidly disintegrated yielding small 
insoluble particulates. However, magnification of the particulate HEC revealed 
that the particles were in fact, thin sheets of film which had coiled about 
themselves thus forming fibers of different lengths dependent on the dye used. 
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The relative length of the fibers was used as an indicator of the integrity of the 
film . It, in conjunction with the overall quantity of insoluble material produced 
was used to determine the "best" dye for future crosslinking studies. 
FD&C Red #40 produced the longest, most continuous fibers of all the 
FD&C dyes tested yet, riboflavin, having an apparently greater yield and wide 
acceptance as a dietary supplement (vitamin 82) was chosen to be the catalyst 
for future investigations. The relatively poor water solubility of riboflavin made it 
difficult to produce a transparent, homogeneous film at required catalyst 
concentrations. A water soluble derivative, riboflavin-5'-phosphate sodium was 
substituted with favorable results . 
Determination of Optimum Polymer - Photocatalyst Ratios 
The effects of polymer molecular weight, catalyst concentration and light 
source are presented in figures 1 - 4. Generally, exposure to light produced 
high yields of insoluble material from films containing catalyst, while those films 
that had not been exposed or lacked catalyst produced little, if any insoluble 
HEC. It should be noted that the apparent production of insoluble HEC in the 
films which lacked catalyst or light exposure is largely due to the inherent 
viscosity of the polymer. The gelled polymer was retained on the filter during 
assay and once dry, did not show evidence of film formation. Also noted was 
the tendency of the riboflavin-5'-phosphate to reduce the gelling tendency of 
films that had not been exposed to light perhaps due to some degree of acid 
hydrolysis (16). 
Table 1 lists the p-values for the main effects and all possible interactions 
for those films exposed to UV and visible light. Analysis of the data from the UV 
study revealed that each of the main effects and their interactions were 
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significant at level of 0.05 (ANOVA). However, individual examination of each 
polymer grade revealed that the amount of UV exposure and catalyst 
concentration were not significant factors for the M grade polymer (p values 
0.149 and 0.07 4 respectively) but were clearly significant for the H grade (p 
values 0.038 and 0.0004) . 
Generally, films of the M grade HEC produced similar amounts of 
insoluble polymer, allowing for quite a variation in amount of catalyst and UV 
exposure while the yield of the "H" films appeared to be catalyst concentration 
dependant. This apparent dependency may be due in part to a decreased 
accessibility of reactive functional groups on the HEC molecule due to the larger 
molecular size of the "H" grade. If that is the case, the lower intra-sample 
variability of the M grade could be explained as its functional groups would be 
more readily accessible to the catalyst. 
The effect of visible light on the HEC - riboflavin-5'-phosphate films was 
also studied but on a scale smaller than that of the UV light study. The results 
of this investigation are presented in figures 3 and 4. Consistent with the UV 
study, films prepared without catalyst tended to form gels that were retained on 
the filter paper and erroneously reported as insoluble. Unlike the UV films, the 
neat films of HEC exposed to visible light continued to form viscous gels after 
prolonged light exposure. However, as in the case of the UV films, the addition 
of riboflavin-5'-phosphate suppressed gelling in films that received no light 
exposure. 
Visible light treatment of the HEC - Riboflavin-5'-phosphate films 
produced the highest yield of insoluble material. Statistical analysis of the data 
revealed that the grade of polymer chosen and all of the interactions containing 
polymer were not significant (see table 1 ). Figures 3 and 4 show that the 
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average percentage of insoluble HEC obtained from films that contained 
catalyst and had been exposed to visible light was routinely in excess of eighty 
percent and quite reproducible. 
Solubility Evaluation 
This study was undertaken to gain a general understanding of how 
photocrosslinked HEC would behave when exposed to different solvents. Since 
the data gathered was not intended to provide an absolute measure of 
solubility, the relative solubilities of the films have been graded on a scale of 1 
to 1 O where 1 represents a solubility less than 10% and 10, a solubility greater 
than 90 %. Results are presented in table 2. 
Water, HCI, NaOH, and Simulated Gastric Fluid USP were chosen to 
simulate conditions encountered in vivo, while acetone and methanol were used 
to determine the behavior of the films in organic media. Additionally , the films 
were subjected to an aqueous urea solution, as urea is a known decoupler of 
hydrogen bonds (11 ). Therefore, a greater solubility in aqueous urea than in 
water would be evident of hydrogen bonding and not chemical crosslinking . 
The control films were quite soluble in aqueous media, although the 
amount of insoluble material obtained from the urea solution was somewhat 
greater. While no detectable remnants of film could be found on the filter, it is 
possible that some polymer may have been retained within the filter paper 
thereby, yielding a slightly higher value for films soaked in the urea solution. 
Those uncrosslinked films exposed to organic media remained continuous and 
largely insoluble as predicted. 
The crosslinking process allowed for great changes in the aqueous 
solubility of the HEC films. Films that were freely soluble prior to crosslinking, 
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( were poorly soluble afterwards. Values obtained from crosslinked films in water 
are consistent with those presented earlier and similar to those of films soaked 
in simulated gastric fluid or aqueous urea. Any apparent difference in the 
values obtained for the three media in table 2, is small although somewhat 
exaggerated since they fall on either side of the 90 % cutoff. Slightly lower 
values were obtained for films soaked in HCI and NaOH. These lower values 
may be due, in part, to some breakdown of the polymer by acid hydrolysis or 
oxidative degradation ( 12). 
Finally, there were no great changes in the solubilities of the control and 
crosslinked films that were soaked in organic solvents. Any apparent difference 
between them in table 2 is somewhat exaggerated due to the actual values 
falling on either side of the 90 percent cutoff. 
Microscopic Analysis of Film Samples 
Representative micrographs of the HEC/riboflavin-S'-phosphate films are 
presented in figure S. Figure Sa, depicts a film sample which had not received 
any light exposure (control sample). The surface of this film is essentially 
smooth and continuous, confirming that it is possible to produce suitable films 
with the method employed. Visible light exposure (7 days@ 1000 ft. can.) did 
not appear to alter the film surface (Sb). A sample of the film depicted in figure 
6 was soaked in water and dried prior to examination (Sc). The micrograph of 
the soaked film confirms that the film remained continuous and nearly 
indistinguishable from the control , except for the appearance of small 
depressions (approx. 20 microns diameter) which do not appear to pass 
through the film . 
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Figures 5d and 5e depict film samples which had been exposed to 
different amounts of UV light (5 and 30 passes, mercury H bulb 600 watts/inch). 
The surface of these films appear to have been altered by the UV exposure as 
small , somewhat circular, areas of different texture appear. The frequency of 
these areas appears to increase with greater amounts of UV exposure. 
Conclusions 
The ability of light, from both visible and ultraviolet sources, to alter the 
aqueous solubility of hydroxyethylcellulose (HEC),irradiated in the presence of a 
photosensitive dye, has been demonstrated. While the exact mechanism of the 
insolubilization has not been determined, it is believed that the changes in HEC 
solubility are a result of crosslinking facilitated by the dyestuff. 
Visible light curing of HEC films that include riboflavin-5'-phosphate as 
the photosensitizer offers the most consistent and reproducible method to alter 
solubility, however long cure times are necessary. Shorter cure times (minutes 
vs. days) are possible when UV light is employed, but the yield of insoluble HEC 
is less consistent and the nature of the light source has a greater potential to 
cause degradation of the film components. 
While there have been other radiation cured coatings, the combination of 
HEC and riboflavin is unique in that it exploits the interaction of two compounds 
which have prior FDA approval for in vivo usage. Prior approval, although not a 
necessity for a prospective new coating, should facilitate its approval provided 
that no new, unknown chemical species have been produced as a result of the 
photocuring process. 
The initial success of this feasibility study warrants further investigation of 
photocured HEC/riboflavin-5'-phosphate films as sustained release coatings. It 
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abil ity to facilitate the prolonged, and consistent release of drugs and other 
bioactive molecules which have been coated in this manner. 
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TABLE 1 
Statistical analysis of Optimum HEC lnsolubilization Parameters 
p - Values 
Main Effects & Interactions UV Light Visible Light 
Polymer MW (P) < 0.001 . 0.161 
#Light Exposure (L) < 0.001 . < 0.001 . 
#Catalyst (C) < 0.001 . < 0.001 . 
P x l < 0.001 . 0.867 
P x C 0.0015 • 0.054 
L x C < 0.001 . < 0.001 . 
( P x l x C 0.039 • 0.567 
• denotes significance at 0.05 level 
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TABLE 2 
Relative solubility of control and visible light cured (7 days@ 1000 footcandles) 
HEC films containing riboflavin-5'-phosphate in various solvents. Numerical 
values in table denote the average amount of insoluble material obtained from 
three separate trials. A value of 1 represents O to 10 % insoluble, 2 represents 
11 to 20 %, 3 represents 21 to 30 % etc .. 
Insolubility of HEC Films 
Solvent Unexposed Exposed 
DI Water 10 
HCL 0.1 N 9 
NaOH 0.1 N 8 
Sim. Gastric 1 9 
Urea 10% aq. 2 9 
Acetone 9 10 
Methanol 9 10 
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( FIGURE 1 
The effect of visible light exposure and riboflavin-5'-phosphate concentration on 
the aqueous solubility of films prepared from M grade HEC 
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FIGURE 2 
The effect of visible light exposure and riboflavin-5'-phosphate concentration on 
the aqueous solubility of films prepared from H grade HEC 
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( FIGURE 3 
The effect of UV light exposure and riboflavin-5'-phosphate concentration on 
the aqueous solubility of films prepared from M grade HEC 
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( FIGURE 4 
The effect of UV light exposure and riboflavin-5'-phosphate concentration on 
the aqueous solubility of films prepared from H grade HEC 
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FIGURE 5 
Scanning electron micrographs depicting surface characteristics of 
photocrosslinkable HEC films containing riboflavin-5'-phosphate: (a) Untreated 
film , (b) Exposed to visible light (1000 ft. can. x 7 days), (c) Exposed to visible 
light (1000 ft. can. x 7 days), soaked in water (24 hrs.) and dried (24 hrs.@ 65 
°C), (d) Exposed to UV light (600 watts/in. for 10 seconds), (e) Exposed to UV 
light (600 watts/in. for 60 seconds) 
57 
( 
FIGURE 5a 
Scanning Electron Micrograph of an Untreated Film 
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FIGURE 5 b 
Scanning Electron Micrograph of a Film Exposed to Visible Light 
( 
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FIGURE 5 c 
Scanning Electron Micrograph of a Film Exposed to Visible Light 
and Washed with Water 
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FIGURE Sd 
Scanning Electron Micrograph of a Film Exposed to Ultraviolet Light 
( 1 O Second Exposure) 
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FIGURE 5 e 
Scanning Electron Micrograph of a Film Exposed to Ultraviolet Light 
(60 Second Exposure) 
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PHOTOCROSSLINKED HYDROXYETHYLCELLULOSE MEMBRANES 
AS SUSTAINED RELEASE COATINGS: ASSESSMENT OF PERFORMANCE IN 
VITRO 
ABSTRACT 
A water insoluble membrane is obtained when films of 
hydroxyethylcellulose (HEC) containing riboflavin-5'-phosphate (R5P) are 
crosslinked via exposure to an appropriate light source. Unlike other 
photocrosslinkable coatings which have been considered for pharmaceutical 
applications, the system presented herein is unique in that it is composed 
entirely of compendia! materials. Tablets that had been designed to function as 
oral osmotic delivery systems when coated with cellulose acetate, containing 
either metoprolol fumarate or dextromethorphan HBr, were coated with the 
experimental materials. Successful coating of the tablets and crosslinking of the 
experimental coatings warranted the determination of drug release rates in vitro. 
Dissolution of tablets with crosslinked coatings was less rapid and considerably 
better controlled than control tablets whose coatings had not been crosslinked. 
The time to 80 percent of tablet label claim released was approximately five 
hours for metoprolol fumarate and slightly greater than 3 hours for 
dextromethorphan HBr upon successful membrane crosslinking. Comparatively, 
uncoated tablets of metoprolol and dextromethorphan each achieved complete 
dissolution 1.5 and 0.5 hours, respectively. In both cases dissolution in 0.1 N 
HCI was more rapid than in water, yet most of this effect may be attributed to the 
increased solubility of the drugs in acid. 
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The Clean Air Act of 1970 and recent, more stringent legislation have 
made the use of large quantities of organic solvents in manufacturing 
prohibitively expensive (1 , 2). As the problems associated with organic solvent 
usage have continued to increase, pharmaceutical manufacturers have turned 
their attention to the various water based coatings which are currently available. 
While the aforementioned coatings offer one possible alternative to those 
requiring organic solvents, there are other options currently under development. 
Recent research provides examples of what appears to be a new trend in 
the development of sustained release solid dosage forms, the in situ 
insolubilized coating (3-6). Coatings of this type exploit materials that, once 
deposited onto the surface of a dosage form , may be converted into durable, 
water insoluble coatings through polymerization and/or crosslinking reactions. 
Generally, these coatings may be divided into two groups. The first of 
these, as exemplified by Wang and Bogner (7) and Yoshida et. al. (5) relies on 
the radiation induced polymerization of monomeric materials to form continuous 
water insoluble coatings. The second, including the methods developed by 
Ishikawa et. al.(6) and Abletshauser et. al.(3) exploits the ability of certain 
polymeric materials to undergo drastic changes in solubility when crosslinked. 
Although each of the aforementioned methods has been demonstrated to 
impart sustained release, the possibility of any of them obtaining regulatory 
approval is rather limited. 
The work of Abletshauser and colleagues may be the exception, as 
calcium alginate is currently included in the French Pharmacopeia, a fact which 
might facilitate its acceptance elsewhere (8). Nonetheless, it is doubtful that the 
alginates are the only GRAS polymers capable of being rendered water 
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( insoluble in situ. Rather it is quite possible that other polymers which equal, if 
not exceed the desired properties of the alginates lie listed in some GRAS list 
awaiting our attention. 
Previously, we had demonstrated that a practically water insoluble film 
could be obtained from water soluble components (HEC/R5P) crosslinked by 
exposure to visible light (9, 10). The coating studied herein is similar to others 
which rely on changes in solubility of the coating components yet, it is unique in 
that it is composed entirely of excipients that are included in the current USP NF 
(11 ). An attempt has been made to assess the sustained release potential of 
this system when applied to tablets that function as oral osmotic drug delivery 
systems. Tablets of this type were chosen for their ability to generate internal 
pressures great enough to challenge the mechanical strength of the test 
coating, a good measure of a films durability, and the fact that osmotic tablet 
coating remains heavily dependent on organo soluble film formers. Model 
drugs were chosen for this study that had different degrees of aqueous 
solubility. Metoprolol fumarate is representative of those drugs that are quite 
water soluble, while dextromethorphan HBr represents those drugs that are 
sparingly soluble. 
MATERIALS AND METHODS 
Materials 
The following materials were obtained from commercial sources and 
used without further purification: Natrosol 250 M pharmaceutical grade 
hydroxyethylcellulose, molecular weight 720,000 (Aqualon Corporation, 
Wilmington, DE), riboflavin-5'-phosphate sodium (Sigma Chemical, St. Louis, 
MO), acetonitrile, HPLC grade (EM Science, Gibbstown, NJ), triethylamine (J .T. 
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( Baker, Phillipsburg, NJ }, hydrochloric acid , acetic acid and ammonium 
hydroxide, all reagent grade (Fisher Scientific, Fairlawn , NJ ), docusate sodium 
and ammonium nitrate, all reagent grade (Aldrich Chemical, Milwaukee, WI ). 
Additionally, uncoated metoprolol fumarate (190 mg) and 
dextromethorphan HBr (20 mg) tablets were provided by Ciba - Geigy. 
Processing 
Coating solution preparation 
Tablets were coated with a solution consisting of the following: Natrosol 
250M (pharma. grade) 1.5% w/w, riboflavin-5'-phosphate 0.031 % w/w, and 
distilled water 98.47%. Both the polymer and riboflavin were dissolved in water 
with a propeller mixer (Lightnin' TSR 1516, 1000 rpm). After several minutes of 
mixing, any agglomerated polymer was dispersed with a homogenizer 
(Silverson L4R, England) run at a low speed so any untoward effects to the 
polymer may be minimized. Once free of undissolved polymer, the coating 
solution was transferred to a darkened refrigerator and allowed to deaerate 
overnight. Solutions were warmed to room temperature prior to coating. 
Tablet coating 
On separate occasions, 1 kilogram of metoprolol fumarate and 1.25 
kilograms of dextromethorphan HBr tablets were charged into a Glatt GC 300 
coating pan (Glatt AG, Switzerland) and preheated to 45°C. The following 
coating parameters were used throughout the study: pan speed = 10 rpm , 
atomizing air = 1.25 bar, inlet air temperature = 55°C, outlet air temperature = 
40 - 45°C, air volume 180 m3/hr. The coating solution was delivered to the pan 
with a peristaltic pump (Masterflex #7526-00) and sprayed through a 0.8 mm 
nozzle tip at an initial rate of four milliliters per minute. Spray rate was gradually 
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increased to, and later maintained, at 10 ml per minute. After a sufficient 
amount of the coating solution had been applied, the pan speed was reduced to 
5 rpm and the tablets were dried for thirty minutes. 
Crosslinking 
Once coated, tablets were arranged on clear glass plates and exposed to 
600 footcandles of visible light within a Hotpack environmental chamber (model 
352642, 25°C) for three or seven day periods. Three day exposed 
dextromethorphan tablets were exposed to 1000 footcandles of visible light. 
Periodically the position and orientation of each tablet, with regard to the lamps, 
was changed to ensure complete exposure to the light source. Once tablets 
had been exposed for their prescribed times, they were removed and stored in 
darkness in sealed containers. 
Release Portal 
A release portal was drilled in those tablets requiring one with a high 
speed mechanical drill (Servo Products Corp. model 7000). Portals were drilled 
so that they completely pierced the tablet coating, but did not penetrate the 
tablet cores to any significant depth. The portal sizes used for the metoprolol 
fumarate and dextromethorphan HBr were: 0.6 and 0.25 mm, respectively. 
Dissolution Testing 
Metoprolol Fumarate 
The release of metoprolol fumarate from HEC/R5P coated tablets was 
studied by USP method I (basket), 100 rpm , 900 ml water, 37°C, n = 6. The 
release rate of metoprolol fumarate in water was determined from tablets in 
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( various stages of the coating process including: uncoated tablets (n = 3), coated 
yet uncrosslinked tablets (n = 3), coated and exposed for three days with and 
without a release portal, and coated and exposed for seven days with and 
without a release portal. Additionally, those tablets with crossl inked coatings 
were tested in 0.1 N HCI. 
One mill iliter samples were drawn according to the following regimen: 0, 
0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, & 12 hours with an automated dissolution sampling 
system (Hanson Research model 75 - 400). Samples were assayed upon 
completion of the dissolution test. 
Dextromethorphan HBr 
The release of dextromethorphan HBr from HEC/R5P coated tablets was 
studied under the same conditions as metoprolol fumarate except the run time 
was shortened to eight hours. Samples were drawn according to the following 
schedule; 0.08, 0.25, 0.5, 1, 2, 3, 4, 5, 6, and 8 hours. 
Assay 
Metoprolol Fumarate 
Interference by riboflavin-5'-phosphate at the analytical wavelength 
necessitated the use of HPLC. Consequently, an HPLC method was developed 
to separate riboflavin-5'-phosphate from metoprolol fumarate. The following 
system was employed: Column: Shodex RSpack 018 - 613 (15 cm) , 
Autoinjector: Waters Wisp 7120 (injection volume: 30 microliters), Pump: 
Shimadzu LC10AS (flow rate: 1.0 ml/min. ), Column heater: Eppendorf CH30 
(45°C), Detector: Shimadzu SPD6AV (I 272 nm, 0.02 AUFS), Integrator: 
Waters 840 chromatographic data station. 
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A mobile phase consisting of ammonium hydroxide (0.61 % solution) 
64.9% w/w, acetonitri le 33.4% and triethylamine 1. 7% adjusted to a pH of 11 .0 
with acetic acid, was prepared fresh prior to each dissolution run. 
The retention time of metoprolol fumarate was approximately 6.1 
minutes. The percentage of metoprolol released was determined by comparing 
the peak area of the sample to that of the mean peak area of bracketed 
standards that represented 190 mg of metoprolol fumarate. 
Dextromethorphan HBr 
As in the case of metoprolol fumarate, interference by riboflavin-5'-
phosphate at the analytical wavelength necessitated the use of HPLC. The 
chromatographic system was identical to that mentioned previously except a 
Waters Microbondpack C18 column (10m particle size 3.9 x 300 mm) was used 
at ambient conditions. Other changes included an analytical wavelength of 280 
nm and an injection volume of 50 microliters. 
The mobile phase for this assay was prepared in the following manner. 
For each liter of mobile phase 700 ml of acetonitrile and 300 ml of distilled water 
were combined. Docusate sodium (2.21 g) and Ammonium nitrate (400.3 mg) 
were added to the mixture which was subsequently adjusted to a pH of 3.05 
with glacial acetic acid, filtered (0.5 micron), and degassed. 
The retention time of dextromethorphan HBr was approximately 5.2 
minutes at a flow rate of 1.25 ml/min.. The percentage of dextromethorphan 
HBr released was calculated by comparing the peak area of the sample to that 
of the mean peak area of bracketed standards which represented 20 mg of 
dextromethorphan HBr. 
71 
( Scanning Electron Microscopy 
Microscopic analysis of HEC/RSP coated metoprolol fumarate tablets 
was used to determine the integrity and continuity of the coating both before 
and after dissolution testing. Micrographs of tablets that had been mounted 
onto aluminum SEM stubs and subsequently sputter coated with gold (Poloron 
E5100, 1 min @ 25Kv) were obtained with a Leica Stereoscan S - 360 
scanning electron microscope. 
RES UL TS AND DISCUSSION 
Background 
Throughout this study, tablets that had been coated with the HEC/RSP 
and crosslinked were compared to both uncrosslinked tablets and uncoated 
core tablets to illustrate the release rate limiting potential of the crosslinked 
coating . The time required to attain the release of 80 percent of the tablet label 
claim (T80%}, 190 mg for metoprolol fumarate and 20 mg for 
dextromethorphan, was used as a comparative measure of the dissolution 
profiles obtained from the various tablets tested. 
Figures 2,3,5 and 6 contain the dissolution profiles of tablets to which a 
release portal has been added in order to gain some understanding of the 
relative permeability of crosslinked HEC films. Both the metoprolol and 
dextromethorphan tablets used in this study had originally been designed to 
function as osmotic delivery systems when coated with cellulose acetate. In 
those systems cellulose acetate acts as a semipermeable membrane allowing 
the influx of water and small ions but not larger molecules (drugs) . As water 
enters the membrane the internal osmotic pressure rises. The rising pressure 
then either causes the rupture of the rigid membrane (undrilled tablet) or 
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initiates the "pumping" of drug through the release portal. The bursting of the 
undrilled membranes during dissolution testing and a gradual near zero order 
release from drilled tablets was assumed to be preliminary evidence of a 
semipermeable membrane. 
Metoprolol fumarate 
Figure 1 compares the dissolution profiles of uncoated metoprolol 
fumarate tablets with those that had been coated with the HEC/RSP coating 
(approx. 16 mg per tablet) and either exposed to visible light (3 or 7 days at 600 
foot candles) or kept in darkness (control). Dissolution of the core tablets (n=3) 
was rapid and variable, yielding a T80% of 30 minutes. Complete dissolution 
was reached in two hours. 
The addition of an HEC/RSP coating to the tablets resulted in prolonged 
drug release, regardless of any post coating treatment. Drug release from the 
control tablets, although prolonged, yielded a T80% of three hours while those 
tablets that had been crosslinked yielded T80%'s of approximately five hours. 
Crosslinked tablets, irrespective of the duration of light exposure, 
produced the most consistent rate and longest duration of metoprolol fumarate 
release (Table 1 ). Following a brief lag time (15 min}, the tablets with 
crosslinked coatings exhibited near zero order release for nearly four hours. In 
comparison, release from the control tablets was less predictable, exhibiting a 
longer lag time (30 min) followed by rapid and irregular drug release. Closer 
examination of the control tablets shows that their release profile, although 
spread out over a longer period, is similar to that of the core tablets. It is 
interesting to note that the release profile of the control tablets is quite similar to 
that of the core tablets if the lag time is disregarded. The similarity between 
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core and control tablets and the marked difference between their release 
profiles and those of the crosslinked tablets may be indicative of two distinct 
mechanisms of release. 
Clearly, release from the core tablets is dictated by erosion. As the tablet 
is wetted, its outermost layers dissolve in the dissolution media thereby 
releasing the drug contained within them. This process continues, assuming 
sink conditions, until all of the drug has gone into solution. Much the same is 
true for the control tablets except drug release is further governed by the 
presence of the uncrosslinked HEC/RSP coating. (Remember that HEC is a 
hydrophillic water soluble polymer and the 16 mg present on each tablet is 
readily soluble in 900 ml of dissolution media.). The lag time exhibited by these 
tablets is most probably a result of delayed core wetting due to the hydration of 
the HEC coating. Once the coating has hydrated, release from the system is 
believed to be determined by a complex mixture of drug release from an 
eroding tablet core that is encased within a swollen, progressively dissolving 
film . Much of the last ten percent of drug release stems from the delay in tablet 
core dissolution affected by the gradual dissolution of the HEC/RSP membrane. 
Once the membrane has dissolved, dissolution of the core tablet , previously 
delayed by the HEC film, proceeds until the entire tablet dissolves and complete 
drug release is obtained. 
Unlike the control tablets, those tablets with crosslinked coatings did not 
completely dissolve during dissolution testing. Empty, swollen, yet continuous 
membranes were recovered from the dissolution vessels after testing of the 
crosslinked tablets was completed. Occasionally, these "shells" were recovered 
intact but with a tear along one side. While the coating may have burst during 
testing, the low inter-tablet standard deviation obtained from each test of 
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( crosslinked tablets suggests that these tears had either a very small effect on 
dissolution rate or, more likely, occurred after the final sample was drawn. The 
recovery of the intact crosslinked HEC/RSP shells in conjunction with the rather 
consistent release obtained from tablets with crosslinked coatings indicates 
membrane controlled diffusion as the principal mechanism of drug release. 
Oddly there was little, if any difference in the dissolution profiles of the three and 
seven day exposed tablets. This may be indicative of a "crosslinking maximum" 
that, once achieved , is not affected by further light exposure. 
As mentioned previously, an attempt was made to ascertain the 
permeability of the crosslinked HEC/RSP membrane by testing the ability of 
drilled tablets to function as osmotic delivery systems. Figure 2 compares the 
release profiles of crosslinked HEC coated tablets with those to which a 0.6 mm 
release portal had been added. The addition of a release portal served to 
increase the average amount of metoprolol fumarate released from three day 
exposed tablets by nearly 10 percent. The release from drilled seven day 
exposed tablets was also faster, although the overall difference between tablets 
with and without a release portal was not as prominent. This indicates that the 
crosslinked HEC/RSP membranes are not semipermeable yet they do serve to 
mediate drug release in a controlled and consistent manner. 
Lastly, in addition to distilled water, the dissolution rate of crosslinked 
tablets (7 day exposure, with and without release portal) was determined in 0.1 
N HCI. Although the insolubility of crosslinked HEC in acid was determined 
previously (9), no predictions could be made as to the effects, if any, that the 
acidic media might have on drug release from tablets with crosslinked coatings. 
The release profi les of tablets tested in water and 0.1 N HCI are presented in 
figure 3. 
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In each case, the release of drug in water is slower than that in acid. 
When dissolution was carried out in acid, the time to T80% ranged from 3.0 
hours for tablets with a release portal to 3.75 hours for those without. By 
comparison, drug release from water was slower, yielding a T80% of 5 hours in 
each case, although the tablets with a portal appeared to release somewhat 
faster in the early part of the dissolution test. This result was not unexpected as 
the solubility of metoprolol fumarate is greater in acid (12). However, the 
differences between water and acid are greater than ten percent at the three 
and four hour time points. Given the rather narrow standard deviation of the 
data, it is possible that the film may be subject to a greater degree of swelling in 
acid, thereby facilitating diffusion and a more rapid release of drug. 
Dextromethorphan HBr 
The dissolution profiles of Dextromethorphan HBr tablets both with and 
without an HEC/R5P coating (7.9 mg/tab) and subjected to different amounts of 
visible light exposure are presented in figure 4. Initially it was hoped that all 
crosslinking could be performed under identical conditions, however a 
malfunction of the 600 footcandle light cabinet necessitated the use of a 
substitute lightsource (1000 footcandles) . Due to the different levels of light 
exposure, no direct comparison of the three and seven day exposed tablets was 
made. 
Presented in figure 4 are the dissolution profiles obtained from the 
various dextromethorphan tablets tested. As one might predict, based on the 
previous discussion of metoprolol dissolution, release from the core tablets was 
rapid, yielding a T80% of 15 minutes and complete dissolution within 30 
minutes. Likewise, release from the control tablets was prolonged (T80% of 
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approx. 1.6 hours), although erratic due to the simultaneous swelling and 
salvation of the uncrosslinked HEC/R5P membrane and the tablet core. 
Crosslinking of the membrane, as in the case of metoprolol, produced 
dextromethorphan tablets which provided rather consistent and considerably 
prolonged release over a several hour period. The T80% for the 3 day, 1000 
footcandle and 7 day, 600 footcandle exposed tablets were approximately 2.8 
and 3.2 hours, respectively. Additionally, near zero order release was obtained 
from the 7 day exposed tablets for nearly four hours while that of the three day 
exposed tablets continued for nearly three (Table 1 ). 
Figure 5 includes dissolution profiles from dextromethorphan tablets with 
crosslinked HEC/R5P membranes tested both with and without a 0.25 mm 
release portal. It appears that the addition of a release portal had a very little 
effect on the dissolution rate of the dextromethorphan tablets. This observation 
is further supported by the dissolution profiles presented in figure 6. 
A comparison of the dissolution rates of dextromethorphan tablets with 
crosslinked HEC/R5P membranes may be found in figure 6. As in the case of 
metoprolol fumarate, the release of dextromethorphan was more rapid in acidic 
media than in water (T80% of 2.5 hours vs. 3.15 hours). Yet unlike the 
metoprolol tablets, and consistent with the profiles in figure 5, the addition of a 
release portal had little effect on the dissolution rate of dextromethorphan in 
either media. While no definite explanation of this occurrence is proposed, we 
postulate that the portal placed in the dextromethorphan tablets was too small 
and thus readily susceptible to blockage by uncrosslinked HEC or other 
components of the core tablets. 
Electron Microscopy 
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Micrographs depicting the surface of the metoprolol fumarate tablets both 
before and after dissolution testing in water are presented in figures 7 and 8. In 
each figure, micrographs designated "a" represent a tablet photographed prior 
to dissolution testing while those designated "b" represent what remains of a 
tablet after the completion of testing. 
Figure 7 reveals both the disappointing fact that the coating contains 
many small holes ranging in diameter from about 0.6 to 0.12 mm. Certainly we 
had hoped to form a continuous membrane and not a microporous one. 
Fortunately, observation of the tablets in the dissolution bath revealed that the 
shell actually swelled, and maintained a considerable internal pressure during 
the course of testing. It is doubtful that this could have occurred if the film 
remained microporous, therefor we postulate that it was possible for the holes 
to be sealed, perhaps by a combination of uncrosslinked polymer and swelling 
of the crosslinked coating . To some extent this idea is supported by figure 7b 
which depicts the remains of a tablet after testing. Drying had caused the shell 
to shrink to 80 percent of its original size. Additionally, it appears that the 
coating contained a far fewer amount of the large, deeply penetrating holes 
(figure 8). At this time it is not known whether the disappearance of the holes is 
an actuality or a remnant of the drying process. Irrespective of that fact, when 
the tablets are recovered from the dissolution media they are swollen, almost 
spherical and able to withhold the osmotic pressure generated by the core 
tablet. Clearly, this observation suggests that the holes may not penetrate the 
coating entirely, or have been sealed upon hydration. 
CONCLUSIONS 
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The idea of an in situ crosslinkable tablet coating, made entirely of 
materials with current regulatory approval has been realized. Through 
prolonged exposure of prototype HEC/RSP films to visible light we have 
demonstrated that an water insoluble film may be obtained from entirely water 
soluble starting materials. The practicality of this technology lies in it's use of 
conventional coating techniques and a simple, and safe source of radiation. 
Although this crosslinking process must still be optimized, this study has shown 
that it is indeed possible to obtain consistent and controlled drug release from 
tablets that have been coated with crosslinkable HEC. 
Indirect evidence has indicated that the crosslinked films in their present 
state, do not provide a semipermeable membrane, although membrane 
mediated diffusion is the most probable method of release. While not a reality 
at this time, a semipermeable membrane might be possible if the coating 
process can be optimized to obtain a more continuous and dense coating. 
Another option may be the addition of a plasticizer to the system although the 
effects of a plasticizer on the "crosslinkability" of the system are not yet known. 
While this paper has illustrated the potential of crosslinked HEC/RSP 
membranes, the photocrosslinking techniques used herein are somewhat 
rudimentary. Obviously if techniques such as this are to become commercially 
viable for drug manufacturing, greater effort must be placed on the 
characterization of the products and processes of crosslinking and the 
determination of the mechanism(s) by which the reactions occur. An 
understanding of the physico-chemical nature of this system, in conjunction with 
positive, rather than inferred proof of the safety of the crosslinked material could 
lead to the regulatory acceptance of this or a similar coating for use in vivo 
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thereby offering the industry a class of coatings which behave quite similarly to 
organo soluble coat ings but without the need for organic solvents. 
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Table 1 
Photocrosslinked HEC/RSP Membrane Dissolution Studies: 
PERCENT LABEL CLAIM RELEASED PER HOUR 
Metoprolol Fumarate Dextromethorphan HBr 
Three Days Seven Days Three Days Seven Days 
Time Control No Hole No Hole Control No Hole No Hole 
(hours) Hole Hole Hole Hole 
1 8 .7 17.3 25.9 19.5 22.9 54.2 30.7 29.6 27.3 29.1 
2 43.9 23.9 24.6 22.2 23.1 42 .0 29.7 26.7 28.4 28.1 
3 27.2 18.0 16.9 16.2 16.6 4 .3 22.4 21.3 22.7 22.7 
4 10.2 12.8 11 .5 13.1 10.2 12.2 15.6 16.0 14.1 
5 0.7 7.9 6.6 7.8 6.8 6 .8 5.4 3.5 4.5 
6 0.7 7.9 6.6 7.8 6.8 
7 4.0 2.1 4.8 3.3 
8 4.0 2.1 4.8 3.3 
9 1.4 0.4 1.6 1.0 
10 1.4 0.4 1.6 1.0 
11 1.3 0.2 1.1 
12 1.3 0.2 1.1 
Note: Balded values represent the mean hourly percent of drug released 
as samples were drawn at two hour intervals 
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Figure 1 
Comparison of Dissolution Profiles: Metoprolol 
Fumarate Osmotic Tablets (190 mg) with and without 
HEC/R5'P coating 
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Note : Exposed tablets were subjected to 600 footcandles of 
visible light. Dissolution media was Water USP. 
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Figure 2 
Comparison of Dissolution Profiles: Metoprolol 
Fumarate Osmotic Tablets (190 mg) coated with 
HEC/RSP with and without 0.6 mm hole 
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Note : Tablets were exposed to 600 footcandles of visible 
light for a period of 3 or 7 days . D1ssolut1on media was 
Water USP. 
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Figure 3 
Comparison of Dissolution Profiles: HEC/R5P coated 
Metoprolol Fumarate Osmotic Tablets (190 mg) in water 
and 0.1 N HCI 
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Note: All tablets exposed to 600 footcandles of visible light 
for 7 days . 
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Figure 4 
Comparison of Dissolution Profiles: 
Dextromethorphan HBr Tablets (20 mg) with and 
without HEC/R5P coating in Water 
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Note: Tablets were e xposed to 600 or 1000 lootcandles of 
visible light for 7 or 3 days , respect ively. 
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Figure 5 
Comparison of Dissolution Profiles: 
Dextromethorphan HBr Tablets (20 mg) coated with 
HEC/RSP with and without 0.25 mm hole 
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Note : Tablets were exposed to either 600 or 1000 footcandles 
of visible light for 1 period of 7 or days , reapectively . 
Dlssolutlon media was Water USP. 
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Figure 6 
Comparison of Dissolution Profiles: HEC/R5P 
coated Dextromethorphan HBr Tablets (20 mg) in 
water and 0.1 N HCI 
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for 7 d1ya. 
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Figure 7 
Scanning Electron Micrographs of Crosslinked HEC/RSP Coated Metoprolol 
Fumarate Tablets before (7a) and after (7b) Dissolution Testing 
Magnification 16.5 X 
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Figure S 
Scanning Electron Micrographs of Crosslinked HEC/RSP Coated Metoprolol 
Fumarate Tablets before (Sa) and after (Sb) Dissolution Testing 
Magnification 75 X 
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ABSTRACT 
A method by which films of water soluble hydroxyethylcellulose may be 
rendered insoluble, after deposition onto the surface of pharmaceutical solids, 
has been developed. While the application of such a technology is rather simple 
and offers promise as a substitute for organic solvent usage, the development of 
meaningful analytical methodology, by which the crosslinking process may be 
monitored and understood has proven rather difficult. Attempts have been made 
to understand and quantify changes occurring to the polymer as a result of the 
crosslinking reaction. Unfortunately many have proven inconclusive. Much of 
the complexity of this problem lies in the insolubility of the crosslinked polymer in 
common aqueous and organic solvents. Therefore considerable attention has 
been paid to analytical techniques which may be performed on materials in their 
solid state. The functional relevance of such techniques, as well as others 
included in our previous work to large scale production is considered herein. 
Additionally included is discussion of alternative techniques which, although not 
tested with this system, may provided useful information about the crosslinking 
process and provided recommendations for other ways to evaluate the 
crosslinked product should instrumental methods fall short of their intended 
goals. 
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INTRODUCTION 
In previous papers we describe a process by which hydroxyethylcellulose 
(HEC}, a water soluble, nonionic polymer may be rendered water insoluble 
through exposure to visible light when in the presence of riboflavin-5'-phosphate 
(1 ). While the insolubilization of HEC has been demonstrated previously, we 
believe our method is unique in that insoluble HEC may be obtained through 
reaction with a photosensitizer that is currently approved for use in vivo (2-4). 
The development of a system containing only GRAS components which may be 
cured with visible light is notable in that previous attempts at radiation cured 
coatings for pharmaceutical solids have suffered the shortcomings of 
unapproved raw materials and the untoward effects of ionizing radiation (5,6). 
In addition to the development of the HEC crosslinking process, (which may 
circumvent the problems associated with unapproved materials) we have 
demonstrated the potential of photocrosslinked HEC as a sustained release 
tablet coating in vitro (7). 
While we are confident that it is possible to alter the aqueous solubility of 
HEC films applied to tablets and prolong the release of the drugs contained 
within those films, our experience with this process has left us with many 
unanswered questions. Simply put, there are aspects of this system that would 
be difficult to characterize, let alone gain an understanding of the nature of the 
chemical changes that have taken place. Fortunately, a complete 
understanding of this system is not a prerequisite to its successful application. 
Still , there exists a need for some reliable indicator of the extent of the 
crosslinking process (quality control) . 
Generally, polymeric materials, especially those derived from natural 
sources, are difficult to characterize. HEC is no exception having no conjugated 
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bonds, thereby ruling out ultraviolet spectroscopy, very poor organosolubility 
and poor water solubility, once crosslinked (1,8). 
Official methods, both compendial (USP/NF) and ASTM, have been 
developed for the identification of, and to set raw material acceptance criteria 
specifications for, HEC (8,9). Unfortunately, these tests do not provide any 
information about the chemical changes that may have taken place as a result 
of the crosslinking reaction. Another official ASTM method which determines 
the ethoxyl substitution of cellulose ethers may provide useful information about 
the polymer if its level of ethoxyl substitution changes as a result of crosslinking 
(10). Unfortunately, the utility of this method remains questionable since the 
chemical changes that may be caused by crosslinking have yet to be 
determined. 
This paper seeks to gain insight into the nature of the crosslinking of 
HEC through common instrumental methods that could be used routinely in a 
quality control setting. The methods included within this work were chosen in 
the hope that they could elucidate any physico-chemical differences between 
crosslinked and control samples of HEC without the need for complex testing 
regimens. While this work has been concentrated on the characterization of 
free films, it is hoped that the methods employed here for films may be readily 
adaptable to coated tablets. 
MATERIALS AND METHODS 
Materials 
Natrosol 250 M pharmaceutical grade hydroxyethylcellulose, molecular 
weight 720,000 was supplied by The Aqualon Corporation (Wilmington, DE) 
while riboflavin-5'-phosphate sodium was purchased from Sigma Chemical 
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Corp. (St. Louis, MO). All materials were used, as received from their 
respective manufacturers without further purification. 
Film Preparation 
All films evaluated in this study were prepared in the following manner. 
Formulation: 
Natrosol 250 M Pharma 
Riboflavin-5'-phosphate 
Water USP 
1.50 % w/w 
0.03 
98.47 
100.00 
The Natrosol and riboflavin-5'-phosphate were weighed and slowly 
added to the vortex of a propeller type mixer (Lightnin' Labmaster TSR 1516) 
operating at 1000 rpm. Any undissolved polymer, which remained after several 
minutes of mixing was dispersed with the aid of a "lab scale" homogenizer 
(Silverson L4R, UK) run at a slow speed so to lessen the possibility of reducing 
the molecular weight of the polymer. Once free of any undissolved polymer, the 
solution was transferred to a darkened refrigerator and allowed to deaerate 
overnight. Prior to fi lm casting, the polymer solution was allowed to warm to 
room temperature. 
Once at room temperature, a suitable portion of the solution was poured 
onto a preheated glass plate (60°C) and spread into a th in film (1.016 mm, wet 
thickness) with the aid of a film casting table (RK Print - Coat Instruments, UK) 
equipped with a # 8 cast ing rod. Once cast, the films were placed into a 
darkened 6o0 c oven and dried for 24 hours. 
Those fi lms used for oxygen permeabil ity testing were placed into an 
environmental cabinet (Forma Scientific) previously calibrated to deliver 1000 
footcandles of visible light at 25°C. Films were exposed to visible light for a 
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period of 4, 8, 16, 24, or 168 hours, removed from the cabinet, and 
subsequently stored in darkness until required. 
Films that were evaluated by DSC, TGA, and IR spectroscopy were 
subjected to either 600 footcandles of visible light for a period of 24 hours 
(Hotpack environmental cabinet, model 352642, 25°C) or evaluated without 
prior light exposure. 
OXYGEN TRANSMISSIBILITY (Dk) 
A Dk1000 Oxygen Permeability Apparatus (JDF Company, Norcross, 
GA) was used for all oxygen transmissibility determinations. Testing was 
performed in accordance with ASTM method 3985 (11) 
Prior to testing each film sample was immersed in ultra pure water until 
fully hydrated. Once hydrated, the films were cut into 1.5 x 1.5 cm squares, and 
reimmersed in water until needed for testing. The thickness of each individual 
square was measured prior to its placement into the diffusion cell (0.35 cm2 
exposed area). 
The test cell of the Dk 1000 was then filled with ultra pure water, sealed 
and subsequently purged with an inert carrier gas (2% H2 and 98% N2) until a 
stable baseline was attained. Once stable, a humidified gas mixture containing 
oxygen and nitrogen (79 and 21 % , respectively) was introduced into the cell. 
Gradually, if the film is permeable, oxygen will diffuse through it and be carried 
to the detector by the carrier gas. At the detector, an electrical current is 
generated and converted to a signal that is directly proportional to the oxygen 
flux through the film (12). 
Wherever possible, Dk measurements were performed in triplicate. 
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IR SPECTROSCOPY 
Infrared spectra of HEC, R5P, and films representative of the different 
stages of the crosslinking process were obtained with the aid of a Nicolet 
Magna 550 FT-IR (Nicolet Instrument Corp. Madison, WI) operated under 
normal conditions. Film samples were run, as received without any further 
preparation while powder samples were finely ground, mixed with KBr and 
compressed into pellets (40 ft.fib . compression force) . Prior to testing, excess 
water and C02 were purged from the sample chamber with nitrogen. After 
purging, each sample was scanned 100 times and its spectra plotted as percent 
transmittance vs. frequency (4000 - 600 cm-1 ). Background spectra were 
gathered each day prior to sample assay. 
DSC, TGA 
Differential scanning calorimetry (DSC) and thermogravimetric analyses 
(TGA) were performed on samples of HEC which had been subjected to 
different amounts of preparation. Films samples, prepared in a manner 
consistent with those mentioned previously, were tested both before and after 6 
days of exposure to 600 watts of visible light and compared to profiles obtained 
for HEC powder tested "as received". 
Calorimetry was performed, in duplicate under nitrogen, with the aid of a 
Perkin Elmer DSC-7 (Perkin Elmer, Norwalk, CT). Samples were heated at a 
rate of 10 CC/min over a temperature range of-60 to 125 oc. 
TGA analyses of HEC samples similar to those evaluated by DSC were 
performed with a Mettler TA 2000 C Thermogravimetric Analyzer (Mettler 
Instruments, Switzerland) under both air and nitrogen. In each case heating 
was maintained at a rate of 4 OC/min over a range of 25 to 600 degrees. 
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RESULTS AND DISCUSSION 
Oxygen Transmissibility 
The oxygen transmissibility (Dk) of hydrogels is largely dependent upon 
two factors, the material itself and the amount of water which it contains. While 
the materials which make up a hydrogel (water excluded) may add a small 
contribution to its overall Dk, its water content appears to have the greatest 
influence on its Dk (12, 13). HEC will readily form hydrogels, a characteristic 
which has been exploited for the creation of sustained release matrices (14) . 
Matrices of this type gradually swell , once hydrated, and continue to do so until 
all of the polymer has dissolved. Much the same can be said for uncrosslinked 
films of HEC/R5P. 
However once crosslinked, HEC/R5P films become insoluble, the degree 
of which is dependent on the amount of crosslinking which has occurred. 
Therefore, based on the statements of the previous paragraph, the Dk of 
HEC/R5P films should decrease as their degree of crosslinking increases. This 
was indeed the case in this study. 
Table 2 displays the effect of different durations of visible light exposure 
on the oxygen permeability of HEC/R5P films. From previous solubility studies 
of crosslinked HEC/R5P films we have learned that the majority of the 
crosslinking which will occur does so within the first 24 hours of exposure, 
although additional exposure beyond 24 hours allows for additional crosslinking. 
Samples that were exposed for 4 and 8 hour periods, although largely insoluble 
in water, were difficult to handle due to their overall weakness when hydrated. 
Because of these difficulties only two tests could be completed for those films 
exposed for 4 hours. 
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Statistical analysis of the oxygen permeability (Table 3) revealed 
significant differences between the mean Dk's of the 168 hour exposed films 
and the remainder of the group except the 8 hour films whose mean had proved 
to be marginally insignificant at an a of 0.05. The outcomes of the t-tests, 
although they must be viewed caut iously because of small sample sizes, 
confirm our observations. The extent of crosslinking of the 4 and 8 hour 
samples is much more variable than that of films exposed for longer periods of 
time. 
Inconsistent crossl inking would allow portions of the HEC film to behave in a 
manner more consistent with that of an uncrosslinked film . Areas of low 
crosslink density would readily absorb large volumes of water and swell 
considerably thereby forming a loose polymeric network which would readily 
allow for the passage of oxygen and other, larger molecules. Conversely, those 
films with relatively high crosslink densities although hydrophilic, resist swelling 
and maintain much of their mechanical strength when hydrated. 
IR Spectroscopy 
Spectra representing various combinations of HEC, R5P and visible light 
exposure are presented in figure 1. A listing of the spectra presented in figure 1 
may be found in table 1. Spectra of neat samples of HEC and R5P have been 
included as controls by which the spectra of crosslinked films may be judged. 
Examination of figures 1 b through 1f reveals no distinct differences 
between the various conditions of exposure below 1500 and above 2500 
wavenumbers. Much of the difference in spectra between 2500 and 1500 
wavenumbers may in fact be due to physical differences in the film samples and 
not any distinct chemical change. Of course the addition of R5P to an HEC film 
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) causes a change in the appearance of the spectrum . Yet the presence, or 
absence of peaks which correspond to those used for the identification of R5P 
(1728, 1648, 1623 and 1578 cm-1) gives some insightto the role which R5P 
has in the changes in HEC solubility encountered upon its exposure to visible 
light (15). 
Within figures 1 d and 1f the benchmark peaks for R5P are clearly 
evident, however they are no longer visible once the crosslinked film has been 
washed with an excess amount of water (Figure 1f). The absence of R5P in 
figure 1f is most encouraging as it leads to the assumption that R5P, or its 
remnants have acted as true catalysts or photosensitizers, facilitating a 
chemical reaction while remaining as separate moieties which may be readily 
removed after accomplishing their intended task. Although a mechanism for 
this reaction has not been determined, Holmstrom has suggested that riboflavin 
is reduced upon exposure to light of sufficient energy (16). While the 
mechanism proposed is beyond the scope of this discussion, it would be safe to 
postulate that the reduced riboflavin has extracted a proton form the most 
readily accessible source, in this case the HEC molecules which constitute the 
majority of the film . 
The ease by which R5P may be extracted from visible light exposed HEC 
films, in conjunction with the notable differences in the aqueous solubilities of 
visible light exposed films with and without R5P (1) leads to the assumption that 
a crosslinking reaction has occurred, facilitated by the presence of a 
photosensitizer. However the lack of significant changes in the infrared spectra 
of the crosslinked films leads us to believe that the crosslinks achieved are few, 
yet numerous enough to have a drastic effect on the polymer solubility. 
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DSC, TGA 
Thermograms of the three HEC samples evaluated are presented in 
figure 2. Little, if any change in the thermal properties of HEC and the 
HEC/RSP mixtures is evident, especially when one takes note that the heat 
flows expressed on the y axis are less than 1 mW overall. Therefore, any 
apparent differences between the respective samples is exaggerated by the 
scale on which they are presented. 
The outcomes of TGA experiments, performed in air and nitrogen, are 
presented in figures 3 and 4 respectively. Detectable mass loss commences at 
about 21 o0 c for samples tested in air and about 22s0 c for samples tested 
under nitrogen. Both of these values are consistent with the 205 to 210 degree 
"browning range" provided in the manufacturers technical literature (14). 
Unfortunately, differences between polymer samples apparent in the TGA plots 
are small and do not allow for the meaningful interpretation of the changes 
imparted to the HEC as a result of the crosslinking reaction. 
CONCLUSIONS 
Although a process by which HEC may be crosslinked through visible 
light exposure has been realized, a determination of what changes, if any, may 
have occurred to the polymer has proven to be most difficult. While a detailed 
mechanistic determination of the reaction between HEC, RSP and visible light 
may be beyond the intended goals of this research, there exists a need for 
analytical techniques by which the success and efficiency of this technique may 
be monitored. Of the three analytical techniques discussed in this work, none 
has provided direct proof of significant chemical changes to the polymer as a 
result of crosslinking. Yet each of them, in some way, has provided insight into 
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the those changes which have taken place. Much of the data gathered, while 
not conclusive of drastic changes imparted by light exposure, is nonetheless 
suggestive of the nature of the few changes which must have occurred to effect 
the alterations in solubility observed and are therefore, invaluable. The real 
value of three of the methods which we had investigated lay in the 
"circumstantial", and not the direct evidence which were gathered from them . 
IR spectroscopy has revealed that no gross changes in the chemical 
structure of HEC were effected as a result of the crosslinking reaction. Yet, our 
attempt to "wash out" the R5P from the crosslinked films revealed that it may 
indeed function as a true catalyst for crosslinking, acting only to facilitate 
changes in the polymer without becoming chemically bound to it. Similarly, 
DSC and TGA investigations demonstrated the similarities, and not differences 
between the crosslinked and control HEC films. 
Circumstantial evidence has led us to postulate that water insoluble HEC 
films are comprised of a weakly crosslinked polymeric network to which 
chemical changes have been effected that are great enough in number to 
impart drastic changes in aqueous solubility, yet few enough to not cause 
significant changes in the polymer's thermal and infrared characteristics. This 
effect may be largely due to the far greater contribution of polymeric inter-chain 
interactions to the mechanical and thermal properties of HEC films, when tested 
in a dry state, than those of the actual crosslinks created through visible light 
exposure ( 17). 
Unlike the circumstantial data proved by IR spectroscopy and thermal 
analyses, oxygen transmissibility testing yielded data which provided a 
quantitative, although quite preliminary, difference between films which had 
been manufactured via different amounts of light exposure. The positive initial 
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result of oxygen permeability testing has demonstrated it's potential value as a 
test method to characterize crosslinked systems and provided hope that future 
research may correlate, quantitatively, amount of crosslinking incurred as a 
result of the dose of light applied. The success of this method is due to the fact 
that measurements are performed on hydrated films. Hydration causes HEC to 
swell considerably. Like other hydrogels, prolonged exposure of uncrosslinked 
HEC to excess water leads to it's eventual salvation. Crosslinking locks 
polymer molecules into fixed structures whose degree of swelling is determined 
by the crosslink density. Therefore, the more crosslinked a polymeric film , the 
less it can swell thereby resulting in a lower overall permeability. 
While we have demonstrated the potential use of oxygen transmissibility 
testing to differentiate between films of differing crosslink densities, the utility of 
this technique for crosslinked tablet coatings remains questionable as it requires 
the use of "free" films. Additionally , time might pose another hurdle since at 
least 2 hours are required to run one sample. 
Although the data gathered from oxygen transmissibility exhibits 
quantitative differences between film samples subjected to different test 
conditions, this test may not prove readily adaptable to an often performed 
quality control procedure as would be required for the manufacture of 
crosslinked tablet coatings. Likewise, the circumstantial evidence derived from 
IR spectroscopy and thermal methods is rarely the basis for a system of quality 
control. Clearly there exists a need for alternative test procedures capable of 
distinguishing the changes that may occur within a photocrosslinkable coating 
system while remaining efficient in both time and cost. 
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At present, the only test which we have found to be both indicative of 
crosslinking and feasible in respect to its use a quality control regimen is the 
rather subjective determ ination of a film's aqueous solubility. This type of 
testing is similar to the "acid bath" tests routinely employed for the evaluation of 
the efficiency of enteric coatings. In the case of crosslinked HEC films, finished 
tablets would be immersed in water and judged by the number of tablets whose 
of coatings fail within a specified time period. Failure of a particular lot of tablets 
would serve to indicate insufficient crosslinking and the subsequent need for 
additional processing. 
Although a solubility test similar to the one previously discussed is a 
reasonable idea, in its' present form it is at best qualitative, and may not be 
capable of discerning the subtle differences in the amount of crosslinking 
incurred by a batch of tablets which may lead to failure of the coating in vivo. 
Surely there are other techniques which, although as of yet untested, may 
assist in the characterization of crosslinked HEC and other polymeric materials. 
In the search for such tests one must remember that some test procedures may 
provide information which may assist in the physico-chemical characterization 
of a polymer, yet have no functional relevance to the performance of a 
crosslinked system containing that polymer. Tests of this type are most useful 
to the theoretical scientist wishes to understand the underlying mechanism by 
which such a crosslinking reaction to occurs. The applied scientist's needs are 
more simple. What he, or she, requires is a battery of test methods which are 
indicative of if, and not necessarily descriptive of the manner in which a suitable 
amount of crosslinking has occurred. 
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Ideally the tests needed to monitor the processing of the type of 
crosslinked coatings explored herein would be those which require minimal 
sample preparation while allowing for the timely testing of many samples. 
Unfortunately such methods may be unattainable. While the search for suitable 
process monitoring assays continues, other actions may be taken to 
characterize the crosslinking process so that reasonable process "end points" 
may be determined. Future studies of photocrosslinked HEC coatings require 
that investigators seek empirical tests which are clearly indicative off the extent 
to which the reaction has occurred. If a simple testing regimen is not readily 
forthcoming , validation of the irradiation process in conjunction with the 
determination of meaningful process limits may offer a suitable means of 
controlling the outcome of the crosslinking process. 
The in situ crosslinked tablet coating technology which we have 
investigated in this, and previous papers, offers promise as a new means of 
creating sustained release pharmaceuticals, yet the technology remains in its' 
infancy. Future investigations need to find meaningful analytical techniques for 
the crosslinked HEC and attempt to define the limits of the irradiation process. 
If these needs are met, and regulatory agencies agree with the assumption that 
a coating made from GRAS materials is itself a GRAS material, pharmaceutical 
formulators may soon have a new sustained release technology at their 
disposal. 
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Table 1 
Combinations of hydroxyethylcellulose and riboflavin-5'-phosphate studied by 
infrared spectroscopy and presented in Figure 1 
Figure Com11osition Ph~sical State Visible Light Ex11osure 
1a Riboflavin-5'-phosphate KBr Pellet None 
1b Hydroxyethylcellulose 250 M Film None 
1c Hydroxyethylcellulose 250 M Film 7 days @ 600 ft. cand. 
1d HEC 250 M and 2 % R5P Film 7 days @ 600 ft. cand. 
1e HEC 250 M and 2 % R5P Film 7 days @ 600 ft. cand. 
1f HEC 250 M and 2 % R5P Film (H20 washed)? days@ 
600 ft. cand. 
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Figure 1 a 
Infrared Spectrum of Riboflavin-5'-phosphate (Obtained from KBr Pellet) 
3800 3000 3'00 3200 3000 2aoo 2e00 2~ 2200 2000 1aoo H•oo HOO 1200 1000 eoo eoo 
W• ...numNrs (c,...1 ) 
) 
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) Figure 1 b 
Infrared Spectrum of Hydroxyethylcellulose (Natrosol 250 M) Free Film 
) 
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Figure 1 c 
Infrared Spectrum of Hydroxyethylcellulose (Natrosol 250 M) Exposed to Visible 
Light (600 footcandles) for 7 Days, Free Film 
3800 3eoo 3'00 3200 3000 2a00 2e00 2600 2200 2000 1aoo 1eoo 1.00 1200 1000 aoo eoo 
w-numt..,.. (em-1 ) 
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Figure 1 d 
Infrared Spectrum of Free Film containing Hydroxyethylcellulose and Riboflavin-
5'-phosphate (2% w/w), No Light Exposure 
3800 3eOC :woo 3200 3000 2eoo 2900 2.00 Z200 2000 1eoo 1eoo 1·"IO 1200 1000 eoo eoo 
w_,.,umbef'l;(cm-1) 
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Figure 1 e 
Infrared Spectrum of Free Film containing Hydroxyethylcellulose and Riboflavin-
5'-phosphate (2% w/w), Exposed to Visible Light (600 footcandles) for 7 Days 
"' '·'° "~~---~-~~-----~-~---""""~----i 
•OOO 3800 3800 3400 3200 3000 2ll00 2900 2400 2200 2000 11100 UIOD 1'00 1200 1000 800 eD0 
W.-numbeni (em-t 
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Figure 1 f 
Infrared Spectrum of Free Film containing Hydroxyethylcellulose and Riboflavin-
5'-phosphate (2% w/w), Exposed to Visible Light (600 footcandles) for 7 Days 
and Subsequently Washed with Distilled Water 
•ooo 3800 3«JO :woo 3200 3000 :zeoo :zeoo 24.00 2200 2000 1llDCI 1800 1"600 1200 1000 1100 eoo 
w._numbtno cm-1 
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Figure 2 
Thermograms of Selected Hydroxyethylcellulose Samples: Reference : Hydroxyethylcellulose 250 
M Powder, Film Sample 1: Film containing HEC 250 M and 2 % w/w Riboflavin 5' Phosphate 
following exposure to Visible Light (600 footcandles, 6 days} , Film Sample 2: Film containing HEC 
250 M and 2 % w/w Riboflavin 5' Phosphate , No light exposure. Note: Samples were heated 
from -60 to 125 degrees centigrade (run 1), cooled and subsequently reheated (run 2). 
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Figure 3 
Thermogravimetric analysis of various Hydroxyethylcellulose s~mples tested in air; Reference: 
Hydroxyethylcellulose 250 M Powder (solid line), Film Sample 1: HEC 250 M and 2 % wlw 
Riboflavin 5' Phosphate following exposure to 600 footcandles of Visible Light for 6 days (dashed 
line) Sample 2: Film containing HEC 250 M and 2 % w/w Riboflavin 5' Phosphate , No light 
exposure {dotted line). 
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Figure 4 
Thermogravimetric analysis of various Hydroxyethylcellulose samples tested under nitrogen; 
Reference: Hydroxyethylcellulose 250 M Powder (solid line), Film Sample 1: HEC 250 M and 2 % 
w/w Riboflavin 5' Phosphate following exposure to 600 footcandles of Visible Light for 6 days 
(dashed line) Sample 2: Film containing HEC 250 M and 2 % w/w Riboflavin 5' Phosphate , No 
light exposure (dotted line). 
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TABLE 2 
The Effect of Visible Light Exposure on the Oxygen Permeability (Dk) of 
Hydroxyethylcellulose Films 
Exposure time 
Trial 1 
Trial 2 
Trial 3 
Mean Dk 
Standard Deviation 
4 hours 
8.20E-10 
1.06E-09 
-
9.40E-10 
1.70E-10 
8 hours 16 hours 24 hours 168 hours 
9.BOE-10 7.90E-10 6.70E-10 5.90E-10 
1.48E-09 7.60E-10 7.BOE-10 5.60E-10 
8.40E-10 6.BOE-10 7.BOE-10 6.10E-10 
1.10E-09 7.43E-10 7.43E-10 5.87E-10 
3.37E-10 5.69E-11 6.35E-11 2.52E-11 
Note: Dk expressed in cc 02/cm2/sec/mm Hg 
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TABLE 3 
Statistical Analysis Comparing the Effect of Visible Light Exposure Duration on 
the Oxygen Permeability (Dk) of Hydroxyethylcellulose Films 
Results of Two Tailed T-Tests 
4 hours 
8 hours 0.601 
16 hours 1.987 
24 hours 1.943 
168 hours 3.866T 
8 hours 
1.810 
1.804 
2.635 
16 hours 
0 
4.363T 
T Denotes significant difference at a = 0.05. 
24 hours 
3.972T 
Note: For comparisons vs. 4 hours, where n=2, total degrees of freedom = 3. 
In all other cases, degrees of freedom = 4. Critical t values for d.f. = 3 
and 4 were 3.18245 and 2. 7765, respectively at a = 0.05 for a two-tailed 
t-test assuming equal variances. 
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GENERAL CONCLUSIONS 
• Within the modern pharmaceutical industry there is a need for new 
coating materials which can prolong the release of medicaments from 
their respective dosage forms. However, due to regulatory constraints 
the chance of a new coating not composed of materials which are 
"generally regarded as safe," ever entering the marketplace is rather 
small. 
• Hydroxyethylcellulose (HEC) , a readily water soluble polymer, may be 
rendered water insoluble through exposure to light, visible or ultraviolet, 
when in the presence of riboflavin 5' phosphate. 
• Visible light exposure of Hydroxyethylcellulose films containing riboflavin 
5' phosphate provides for superior yeilds of insoluble polymer than does 
irradiation with ultraviolet light under the test conditions studied. 
• Once crosslinked, HEC is practically insoluble in water, acidic and basic 
media (0.1 N), acetone, methanol, and aqueous urea. As urea is a 
known decoupler of hydrogen bonds, hydrogen bonding is believed not 
to be a significant cause of the polymer's change in solubility. 
• The idea of an in situ crosslinkable tablet coating for the sustained 
release of mediaction has been realized. Such a coating may be applied 
with extant technologies and be rendered insoluble via exposure to 
visible light. 
• The ability of crosslinked HEC membranes to prolong and control the 
release of both metoprolol fumarate and dextromethorphan HBr has 
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been demonstrated in vitro. The mechanism of release does not appear 
to be that of a semipermeable mebrane but rather membrane mediated 
diffusion. 
• Although the crosslinking of HEC has been facilitated, analysis of the 
crosslinked product has proven to be most difficult. Aside from relatively 
qualitative solubility and swelling tests which can demostrate the 
differences between samples which had been subject to different test 
conditions, more quantitative techniques have proven elusive. 
• Data gathered from infrared spectroscopy, differential scanning 
calorimetry, and thermo gravimetric analysis has proven to be largely 
circumstantial in nature. While no direct changes to the polymer are 
observed, their lack leads to the assumption that what changes have 
occurred are too small in number to be detected by these methods, yet 
numerous enough to drastically alter the solubility of HEC. 
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SECTION Ill 
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• Appendices 1, 2, and 3. 
• Complete listing of references cited. 
) 
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APPENDICES 
1. ASSAY VALIDATION: METOPROLOL FUMARATE 
2. ASSAY VALIDATION: DEXTROMETHORPHAN HBr 
3. UNITED STATES PATENT APPLICATION: "RADIATION CURED 
DRUG RELEASE CONTROLLING MEMBRANE" 
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Appendix 1 
Assay validation report for metoprolol fumarate samples 
in water and in 0.1 N HCI 
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Appendix 1 
Assay validation report for metoprolol fumarate samples 
in water and in 0.1 N HCI 
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ASSAY VALIDATION: 
METOPROLOL FUMARATE TABLETS COATED WITH PHOTOCROSSLINKED 
HYDROXYETHYLCELLULOSE 
1. SOURCE of STANDARD: 
Metoprolol fumarate, Lot# S-2-92-24, was prepared by the Chemical 
Development Department, Ciba - Geigy Pharmaceuticals, Summit, NJ and 
subsequently assayed and released for use as a reference standard by 
the Physical and Analytical Chemistry Department, Ciba - Geigy 
Pharmaceuticals, Suffern, NY ( attachment 1 ). 
2. ASSAY: 
Pump: 
Injector: 
Column Heater: 
Column: 
Detector: 
Integrator: 
Parameters: 
Flow Rate: 
Injection Volume: 
Temperature: 
Detector: 
Solutions: 
Shimadzu LC10AS 
Waters WISP 712D 
Eppendorf CH30 
Shodex RS Pack D18-613 (15 cm) 
Shimadzu SPD6AV, UVNIS 
Waters 840 Chromatographic Data Station 
1.0 ml/min. 
30 µL 
45oC 
A. 272 nm, 0.02 AUFS 
Ammonium Hydroxide (0.61 %) 
Add 22 ml of ammonium hydroxide to approximately 500 ml distilled water 
in a 1 liter volumetric flask, mix well , and dilute to volume with distilled 
water. 
Mobile Phase: 
In a suitable flask combine 340 ml of acetonitrile, 660 ml of ammonium 
hydroxide (0.61 %), and 34 ml of triethylamine. Mix well and degas under 
vacuum for 1 O minutes. Adjust pH to 11 .0 with acetic acid and filter through 
a 0.5 µ Millipore filter, or equivalent, before use. 
3. REPRESENTATIVE CHROMATOGRAMS: 
The chromatograms presented in figures 1 through 9 represent the various 
components present in the final , coated dosage form. They are as follows: 
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Figure# 
1 
2 
3 
4 
5 
6 
7 
8 
9 
Description Concentration (mg/mil 
Water Blank n/a 
Metoprolol Fumarate in Water 2.412x10-1 
Riboflavin 5' Phosphate in Water 4.038x10-" 
Metoprolol Tablet (Uncoated) Water 2.11x10-1 (drug) 
Metoprolol Tablet (Coated) 2.11x10-1 (drug) 
HCI Blank 0.1 N 
Metoprolol Fumarate in HCI 2.423x10-1 
Riboflavin 5' Phosphate in HCI 4.038x10-4 
Metoprolol Tablet (Uncoated) HCI 2.11x10-1 (drug) 
The retention time of metoprolol fumarate was approximately 6.0 minutes 
when assayed by this method. 
4. LINEARITY: 
The linearity of metoprolol fumarate in both distilled water and 0.1 N HCI 
was determined by simple linear regression ("Cricket Graph" graphing 
software, Computer Associates International, Inc. Islandia, NY). In each 
case, seven separate concentrations of metoprolol fumarate were used to 
generate the standard curve. Figure 10 depicts the standard curve, and 
linear regression of metoprolol fumarate in water while figure 11 depicts 
that of metoprolol fumarate in 0.1 N HCI. 
The following concentrations were used for each linearity determination: 
Solution# 
1 
2 
3 
4 
5 
6 
7 
Cone. in Water (mg/mil 
2.412x10-1 
2.171x10-1 
1.447x10-1 
9.648x10-2 
4.824x10-2 
1.929x10-2 
4.824x10-3 
Cone. in 0.1 N HCI (mg/mil 
2.423x10-1 
2.180x10-1 
1.454x10-1 
9.692x10-2 
4.846x10-2 
1.938x10-2 
4.846x10-3 
Suitable linearity was obtained in each case. Correllation coefficients for 
linearity determinations in water and 0.1 N HCI were 9.995x10-1 and 
9. 997x1 0-1, respectively. 
5. PRECISION: 
Assay precision was determined by plotting the peak areas of triplicate 
injections of metoprolol fumarate samples of known concentration against 
the standard curves generated in the previous section. The mean % 
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difference between the actual concentration of the samples and that 
determined by the standard curve did not exceed 2.0% for any of the 
individual concentrations/injections tested (see below). Plots of each 
individual injection vs. their corresponding standard curve are presented in 
figures 12 and 13. 
Equation 1. Linearity of metoprolol fumarate in water: 
Cone. metoprolol fumarate = 5.4435x1 Q-3 + 3.1563x10-1 x PEAK AREA 
Sample# Cone. (actual) Cone. (by Eq. 1) % Difference 
(mg/ml) (mg/ml) (cone.actual vs. by eg. 1) 
1a 1.998x10-1 2.034x10-1 1.80 
1b 1.998x10-1 1.999x10-1 0.05 
1c 1.998x10-1 2.045x10-1 2.35 
2a 9.999x10-2 1.004x10-1 0.41 
2b 9.999x10-2 1.005x10-1 0.58 
2c 9.999x10-2 1.005x10-1 0.58 
3a 4.995x10-2 5.017x10-2 0.44 
3b 4.995x10-2 5.068x10-2 1.46 
3c 4.995x10-2 5.178x10-2 3.67 
Equation 2. Linearity of metoprolol fumarate in 0.1 N HCI: 
Cone. metoprolol fumarate = 3.8207x10-3 + 3.2073x10-7 x PEAK AREA 
Sample# Cone. (actual) Cone. (by Eq. 1) % Difference 
(mg/ml) (mg/ml) (cone.actual vs. byeg. 
1a 2.039x10-1 2.057x10-1 0.85 
1b 2.039x10-1 2.083x10-1 2.13 
1c 2.039x10-1 2.077x10-1 1.83 
2a 1.019x10-1 1.006x10-1 1.35 
2b 1.019x10-1 1.016x10-1 0.37 
2c 1.019x10-1 1.025x10-1 0.51 
3a 5.099x10-2 5.048x10-2 1.00 
3b 5.099x10-2 4.997x10-2 2.00 
3c 5.099x10-2 5.003x10-2 1.88 
6. SYSTEM SUITABILITY 
System suitability tests were performed prior to each dissolution run 
according to the specifications set forth in USP XXll. In each case, the 
mean peak area and standard deviation of six replicate injections of a 
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metoprolol fumarate standard solution were determined. Rejection was 
made if the peak area standard deviation was found to be in excess of 2.0 
percent. 
Historical system suitability data is presented in attachment 2. 
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Figure 1 
Chromatogram of Distilled Water 
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Figure 2 
Chromatogram of Metoprolol Fumarate in Distilled Water 
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Figure 3 
Chromatogram of Riboflavin 5' Phosphate in Distilled Water 
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Figure 4 
Chromatogram of Metoprolol Fumarate Tablet (uncoated) 
in Distilled Water 
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Chromatogram of Metoprolol Fumarate Tablet (coated) 
in Distilled Water 
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Figure 6 
Chromatogram of 0.1 N HCI 
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Figure 7 
Chromatogram of Metoprolol Fumarate in 0.1 N HCI 
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Figure 8 
Chromatogram of Riboflavin 5' Phosphate 0.1 N HCI 
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Figure 9 
Chromatogram of Metoprolol Fumarate Tablet (uncoated) 
in 0.1 N HCI 
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Figure 10 
Linearity: Metoprolol Fumarate in Water 
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Figure 11 
Linearity: Metoprolol Fumarate in 0.1 N HCI 
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Figure 12 
Precision: Metoprolol Fumarate Samples vs. 
Standard Curve in Water 
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Figure 13 
Precision: Metoprolol Fumarate Samples vs. 
Standard Curve in 0.1 N HCI 
Note : Three Injections for each concentration 
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Attachment 1 
CIBA-GEIGY. CORPORATION 
Physical and ~nalytlcal Chemistry 
(Reference Standard) 
METOPROLOL FUMARA.TE 
1-Iaopropylamino-3-(p-( 2-methoxyethyl} phenoxyl J-2-propanol ( 2: l) 
Fumarate Salt 
Reference Standard No .: S-2-92-24 
Source: Chemical Development, . Summit 
(Reaaaay of S-2-87-20) 
Sample Designation: CDF 2232 (Sample No . 83-695) 
JI.mount availablet 299 qrama 
Kay 27, 1992 
Reasaay Date: May, 1997 
Recommended Storage C~:mdition: 
Recommended Diepens inq Inatructione: 
Structure: 
Store in an amber glass bottle at room 
temperature. 
Dispense approximately S qrama per 
bottle. 
[~/""'"""""] 
CH~20CH3 
HOOC H 
\ I 
C•C 
I \ 
H COOH 
' 
Molecular Weight: 650. 79 Empirical Formula: C,..Hs.tff~10 
1. Description: 
Clean, white crystalline powder. 
2. Spectroscopy: 
Infrared Spectrum 
The infrared spectrum, obtained as a nujol mull, is comparable to 
the previous metoprolol fumarate reference standard S-2-87-20. The 
following assignments are consistent with the structure of 
metoprolol fumarate. 
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Wavenumber rem·•) Aaa ignmenta 
1612 
1517 
1244 
1195 
1113 
1051 
990 
812 
Aromatic ring, carboxylate ion 
ArOCDatic rin9 
Aromatic ether 
taopropyl qroup 
Aliphatic ether, •econdary alcohol 
1-4 Di•ub•tituted benzene 
C•C 
1-4 Diaub•tltuted benzene 
J. Chromatographic Impurities - Liauid Chromatography/Thin Layer 
Chromatoqraphyt 
Thin-Layer Chromatography: 
CHClJ (under Nils atmosphere], Silica Cal CF 254, 250 µm layer: At 
the 200 µ9 level. Total impurities detected leas than O.l\. 
b. Liquid Chrsxpatography: 
LC \: 1.mpuritiea • O.l\: (by percent area normalization) 
LC + TLC total impurities • 0.2\ 
Column: 
·Mobile Pha•e: 
Detection: 
Sensitivity: 
Flow Bate: 
Temoerature: 
µBondapak c11 (Water• A••ociate•, 30 cm x 3.9 mm IO) 
Acatonitrile/waur (380 mL/1620 mL) containinq 7. 8 qm 
of umoniu.m aceta.te, 4. 0 mL of triethylam.ine, 20 mL 
ot qlacial acetic acid, and 6.0 mL of phosphoric 
acid. 
Ultra.viOlet detector (275 nm} 
0.01 AUFS 
1 mL/minute 
4oac 
4. Losa on prying - pry at 60•c under vacuum tor tour hour•: 
0.02' 
S. aaaa.y - Nonaoueoua titration <HClO.l: 
99. S\ (dried baoio) 
Thia material la auitable for use a.a a. reference atandard for Lopraaaor. 
Reference: . NB-132 RIC #67 /130 
~.b. 
RX:ap 
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Run Date 
Mg Eq. Standard 
Injection# 
1 
2 
3 
4 
5 
6 
Mean Peak Area 
Standard Dev. 
Rsd% 
Run Date 
Mg Eq. Standard 
Injection# 
1 
2 
3 
4 
5 
6 
Mean Peak Area 
Standard Dev. 
Rsd% 
Attachment 2 
SYSTEM SUITABILITY DATA 
Metoprolol Fumarate Assay 
Acceptance Criteria: rsd > 2.0% 
11/3/93 11/12/9311/16/9311/17/94 
188.64 194.81 194.81 188.17 
Peak Peak Peak Peak 
area area area area 
633962 641233 696370 649744 
628092 640588 708284 645780 
629994 647129 713181 640102 
627219 642045 707666 641716 
623836 640102 727169 639494 
627351 647397 721446 634094 
628409.00 643082.33 712352.67 641821 .67 
3079.40 3016.40 9973.82 4941 .91 
0.490 0.469 1.400 0.770 
5/8/94 5/10/94 5/13/94 5/16/94 
180.81 190.00 190.00 197.86 
Peak Peak Peak Peak 
area area area area 
649420 664148 669201 694088 
628946 661572 663634 693349 
643949 654365 662022 685917 
634409 661266 662251 696255 
629780 660908 661826 692735 
663134 656475 661153 689348 
641606.33 659789.00 663347.83 691948.67 
12123.87 3317.03 2721 .38 3387.35 
1.890 0.503 0.410 0.490 
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5/4/94 5/6/94 
180.81 180.81 
Peak Peak 
area area 
617486 625682 
619004 610162 
616919 618400 
619151 618656 
623214 622584 
622220 616304 
619665.67 618631 .33 
2313.48 4874.01 
0.373 0.788 
5/17/94 5/20/94 
197.86 190.03 
Peak Peak 
area area 
697328 670669 
698670 690437 
701430 673783 
701116 661335 
692355 665846 
705019 656580 
699319.67 669775.00 
3938.23 10836.36 
0.563 1.618 
Appendix 2 
Assay validation report for dextromethorphan HBr samples 
in water and in 0.1 N HCI 
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ASSAY VALIDATION: 
DEXTROMETHORPHAN HBR TABLETS COATED WITH 
PHOTOCROSSLINKED 
HYDROXYETHYLCELLULOSE 
1. SOURCE of STANDARD: 
Dextromethorphan HBr, Lot# S-1-90-17, was prepared by the Chemical 
Development Department, Ciba - Geigy Pharmaceuticals, Summit, NJ and 
subsequently assayed and released for use as a reference standard by 
the Physical and Analytical Chemistry Department, Ciba - Geigy 
Pharmaceuticals, Suffern, NY ( attachment 1 ). 
2. ASSAY: 
Pump: 
Injector: 
Column: 
Detector: 
Integrator: 
Parameters: 
Flow Rate: 
Injection Volume: 
Temperature: 
Detector: 
Solutions: 
Mobile Phase: 
Shimadzu LC10AS 
Waters WISP 7120 
Whatman Partisil 5 ODS - 3 (15 cm) 
Shimadzu SPD6AV, UVNIS 
Waters 840 Chromatographic Data Station 
1.25 ml/min. 
50 µL 
Ambient 
I.. 280 nm, 0.01 AUFS 
In a suitable flask combine 700 ml of acetonitrile, 300 ml of distilled water, 
2.21 g docusate sodium and 400.3 mg ammonium nitrate. Mix well and 
degas under vacuum for 10 minutes. Adjust pH to 3.05 with acetic acid and 
filter through a 0.5 µMillipore filter, or equivalent, before use. Discard after 
twenty four hours. 
3. REPRESENTATIVE CHROMATOGRAMS: 
The chromatograms presented in figures 1 through 9 represent the various 
components present in the final , coated dosage form. They are as follows: 
Figure # Descript ion 
1 Water Blank 
2 Dextromethorphan HBr in Water 
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Concentration (mg/mil 
n/a 
4.0x10-2 
) 
3 
4 
5 
6 
7 
8 
9 
Riboflavin 5' Phosphate in Water 
Dextromethorphan Tablet (Uncoated) Water 
Dextromethorphan Tablet (Coated) 
HCI Blank 
Dextromethorphan HBr in HCI 
Riboflavin 5' Phosphate in HCI 
Dextromethorphan Tablet (Uncoated) HCI 
4.038x10-4 
4.0x10-2 (drug) 
4.0x10-2 (drug) 
0.1 N 
4.01x10-2 
4.038x10-4 
4.0x10-2 (drug) 
The retention time of Dextromethorphan HBr was approximately 5.1 
minutes when assayed by this method. 
4. LINEARITY: 
The linearity of Dextromethorphan HBr in both distilled water and 0.1 N HCI 
was determined by simple linear regression ("Cricket Graph" graphing 
software, Computer Associates International, Inc. Islandia, NY). In each 
case, seven separate concentrations of Dextromethorphan HBr were used 
to generate the standard curve. Figure 10 depicts the standard curve, and 
linear regression of Dextromethorphan HBr in water while figure 11 depicts 
that of Dextromethorphan HBr in 0.1 N HCI. 
The following concentrations were used for each linearity determination: 
Solution# 
1 
2 
3 
4 
5 
6 
7 
Cone. in Water (mg/mil 
7.946x10-2 
3.973x10-2 
3.178x10-2 
2.543x10-2 
1.589x10-2 
7.946x10-3 
2.384x10-3 
Cone. in 0.1 N HCI (mg/mil 
8.012x10-2 
4.006x10-2 
3.205x10-2 
2.564x10-2 
1.602x10-2 
8.012x10-3 
2.404x10-3 
Suitable linearity was obtained in each case. Correllation coefficients for 
linearity determinations in water and 0.1 N HCI were 9.995x10-1 and 
9. 997x10-1, respectively. 
5. PRECISION: 
Assay precision was determined by plotting the peak areas of triplicate 
injections of Dextromethorphan HBr samples of known concentration 
against the standard curves generated in the previous section. The mean 
% difference between the actual concentration of the samples and that 
determined by the standard curve did not exceed 4.4% (mean % 
differences: 2.11 for water and 1.62 for 0.1 N HCI) for any of the individual 
concentrations/injections tested (see below). Plots of each individual 
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injection vs. their corresponding standard curve are presented in figures 12 
and 13. 
Equation 1. Linearity of Dextromethorphan HBr in water: 
Cone. Dextromethorphan HBr = 2.8207x1o-4 + 7.9307x10-8 x PEAK AREA 
Sample# Cone. (actual) Cone. (by Eq. 1) % Difference 
(mg/ml) (mg/ml) (cone.actual vs. bl£'. eg. 1 l 
1a 2.861x10·2 2.935x10-2 2.59 
1b 2.861x10·2 2.987x10-2 4.40 
1c 2.861x10·2 2.955x10·2 3.29 
2a 1.907x10-2 1.951x10-2 2.31 
2b 1.907x10-2 1.954x10-2 2.46 
2c 1.907x10-2 1.928x10·2 1.10 
3a 4.768x10-3 4.787x10-3 0.40 
3b 4.768x10-3 4.837x10-3 1.45 
3c 4.768x10·3 4.721x10-3 0.98 
Equation 2. Linearity of Dextromethorphan HBr in 0.1 N HCI: 
Cone. Dextromethorphan HBr = 2.0129x10-4 + 7.75535x10-8 x PEAK AREA 
Sample# Cone. (actual) Cone. (by Eq. 1) % Difference 
(mg/ml) (mg/ml) (cone.actual vs. bl£'. eg. 1) 
1a 2.884x10·2 2.927x10·2 1.49 
1b 2.884x10-2 2.960x10-2 2.64 
1c 2.884x10-2 2.957x10-2 2.53 
2a 1.923x10-2 1.957x10-2 1.77 
2b 1.923x10-2 1.951x10-2 1.46 
2c 1.923x10-2 1.935x10-2 0.62 
3a 3.205x10-3 3.186x1 Q-3 0.59 
3b 3.205x10·3 3.295x10-3 2.81 
3c 3.205x10-3 3.226x10-3 0.65 
6. SYSTEM SUITABILITY 
System suitability tests were performed prior to each dissolution run 
according to the specifications set forth in USP XXll . In each case, the 
mean peak area and standard deviation of six replicate injections of a 
Dextromethorphan HBr standard solution were determined. Rejection was 
made if the peak area standard deviation was found to be in excess of 2.0 
percent. 
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Historical system suitability data is presented in attachment 2. 
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Figure 1 
Chromatogram of Distilled Water 
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Figure 2 
Chromatogram of Dextromethorphan HBr in Distilled Water 
VA.IL.ID 2 ·4-May-94 .l.2:47 i0 7 
Prlntad 011 2i-H.,y-9t at 15 12.2.:0S 
A.cquiallion •ethod 
Un 1l:s 
Chanrud 
luJecliun 
Run t i•e 
lnjecllon volu•e 
Acqu1:sitlon version 
UY/VIS 
DEXTRO 
7.00 •ln 
50 UL 
6.2.1 
Quantilation •ethod 
Sysle• uu•her 
Y 1al 
Total u 1Jact1011s 
Sa•ple rate 
Hoda 
Quan ti tatJ.on version 
HPLC analysis PHOTOCOATED DEXTRO HBR TABS 20 HG 
MEDIA: WATER 
OEXTRO in WATER 
Chro•atogra• of VAILID 
i.:::~ ~ 
;ti',' 
"" :;. lUlj :s 
"' "' 
.;..:i i ii 
' i ,, .. " I\ :~I"' -< i I I I 
DEXTRO 
91 
1 
1.00 per aec 
Calibration 
6.2.l 
I ( 
I 
' I ~ 
I 
r 
I [ 
Peak Vue Ret the Area Belgbt Typ!! Responui Oevhtlon lglercept Sloee 
OEITROHETHORPHAM 5.H 511661 52.02.0 BB S.11667e•OS 3. l 702e•OS 0 . OOOe+OO 2.. 099e•Ot 
154 
) 
Figure 3 
Chromatogram of Riboflavin 5' Phosphate in Distilled Water 
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Figure 4 
Chromatogram of Dextromethorphan HBr Tablet (uncoated) 
in Distilled Water 
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Figure 5 
Chromatogram of Dextromethorphan HBr Tablet (coated) 
in Distilled Water 
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Figure 6 
Chromatogram of 0.1 N HCI 
VAIL.ID 2-.lt-May-94 13:04:55 
Printed 011 2•-Hay-9-t at 15:21:•6 
Acqu.Ls1t1011 11ethod 
Unit.1:1 
Channel 
luJeclion 
Run tiae 
lnJectlon voluae 
Acqulsltlon version 
UV/VIS 
DEXTRO 
7,00 a1n 
SO uL 
6.21 
Quantltallon method 
Svs t.ua nu•ber 
v·u1 
Tola l 1n.t&ct.1011s 
Saaple rate 
Ho de 
Quantitallon vers1on 
_HPLC analysts PHOTOCO ATED DEXTRO HBR TABS 2.0 HG 
0 , l N HCL 
Chromatoqraa of VAILID 
:;.'} 
j 
~ 
" Ii ,, 
II 
I\ 
i '. 
I '"\ 
·' I ,, J·i~ 
DEXTRO 
l 
93 
1 .00 per aec 
Cal lbrat.1or1 
6.21 
Peak IHe Area Helght TyP' Ruoonn Deviaqon Intercept 
DEITROHETHORPHAM 5.15 
- If 
158 
Slone 
) 
Figure 7 
Chromatogram of Dextromethorphan HBr in 0.1 N HCI 
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Figure 8 
Chromatogram of Riboflavin 5' Phosphate 0.1 N HCI 
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Figure 9 
Chromatogram of Dextromethorphan HBr Tablet (uncoated) 
in 0.1 N HCI 
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Figure ·10 
Linearity : Dextromethorphan HBr in Water 
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Figure 11 
Linearity: Dextromethorphan HBr in 0. 1 N HCI 
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Figure 12 
Precision: Dextrornethorphan HBr Samples vs. 
Standard Curve in Water 
Note : Three injections at each concentration 
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Figure 13 
Precision: Dextromethorphan HBr Samples 
vs. Standard Curve in 0.1 N HCI 
Note : Three injections at each concentration 
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Attachment 1 
CIBA-GEIGY CORPORATION 
Physical and Analytical Chemis try 
(Reference Standard) 
Dextromethorphan Hydrobromide 
Reference Standard No . : S-1-90-17 (Reassay of S-1-85-21) 
Source: Chemical Development, Summit 
Sample Designation: Batch No . NA-1-97 
Amount Available: 971 g 
Date : June 1, 1990 
Reassay Date: June, 1995 
Recommended Storage Conditions: Store in a tight, light-resistant 
container 
Structure : 
Molecular Weight: 370 . 33 
1 . Description: 
White crystalline powder . 
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2. Infrared Spectroscopy: 
The spectrum is consistent with the structure indicated. 
3283 
2926,2857 
1616 
1576, 1498 
1463 
1281,1170 
Assignments 
C-H stretching 
-CH2 bending 
H-0 stretching 
C=C stretching, aromatic ring 
-CH3 bending 
1244, 1071, 1042 
86 7. 775. 727 '693 
C-N stretching, tertiary amine 
-OCH3 stretching 
C-C out-of-plane bending, aromatic ring 
3 . Liquid Chromatography : 
Column : 
Mobile Phase : 
Detector : 
Flow Rate : 
Sensitivity: 
Temperature: 
Assay: 
4 . Identification : 
µBondapak C18 (llaters) 30 cm x 3 . 9 Diil ID , or 
equivalent 
Dissolve 3.1 g of docusate sodium in 1000 mL of 
acetonitrile/water (70 : 30), add 560 . 4 mg of 
ammonium nitrate, adjust the pH to 3 . 4 with 
acetic acid, mix and filter the solution through 
a 0 . 45 µm Millipore FH filter (or equivalent) . 
Degas the mobile phase before use. 
UV - 280 nm 
l mL/minute 
0.1 AUFS 
Ambient 
99 . 6'1,,-anhydrous basis (external standard method) 
4 . 1 Infrared Absorption : 
Conforms to previous reference standard . 
4 . 2 Ultraviolet Absorption : 
Conforms to previous reference standard . 
Absorptivity of sample vs . USP reference standard= 0 . 78'1. 
(anhydrous basis) 
4.3 Bromide: 
Positive 
5 . pH (l in 100) : 
5 . 5 
6 . Water Content : 
4 . 72'1. 
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This sample is suitable for use a s a reference standard in testing 
o f Dextromethorphan Hydro bromide . 
Reference: HB #94/52 
ti. Bordun 
HB:ap 
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Run Date 
Mg Eq. Standard 
Injection# 
1 
2 
3 
4 
5 
6 
Mean Peak Area 
Standard Dev. 
Rsd% 
) Run Date Mg Eq. Standard 
Injection# 
1 
2 
3 
4 
5 
6 
Mean Peak Area 
Standard Dev. 
Rsd% 
Attachment 2 
SYSTEM SUITABILITY DATA 
Dextromethorphan HBr Assay 
Acceptance Criteria: rsd > 2.0% 
5/26/94 5127194 5/31/94 6/1/94 
20.67 20.67 20.88 20.68 
Peak Peak Peak Peak 
area area area area 
537812 535713 541428 529917 
538292 536078 544172 531170 
538087 530820 540179 533341 
537131 518856 542329 534753 
533114 521248 539765 536848 
529696 518993 544293 530106 
535688.67 526951 .33 542027.67 532689.17 
3205.70 7488.07 1766.24 2537.90 
0.598 1.421 0.326 0.476 
6/10/94 6/12194 6/14/94 
19.86 19.57 19.57 
Peak Peak Peak 
area area area 
519894 519673 513199 
523396 520254 515779 
524883 516610 516325 
527527 521182 512937 
519913 522027 516220 
505843 519322 518435 
520242.67 519844.67 515482.50 
6977.56 1707.06 1904.07 
1.341 0.328 0.369 
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6/2194 6nt94 
20.68 19.86 
Peak Peak 
area area 
541938 438031 
542156 437841 
539409 437693 
540720 435689 
539939 435679 
543389 435608 
541258.50 436756.83 
1369.79 1102.81 
0.253 0.252 
) 
Appendix 3 
United States Patent Application entitled: "Radiation Cured Drug Release 
Controlling Membrane" and documents concerning its receipt by U.S. Patent 
Office. 
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CGC 1740 
RADIATION CURED DRUG RELEASE CONTROLLING 
MEMBRANE 
Inventor: Gary Van Savage, residing at 1 O Flanders Way, Bridgewater, New 
Jersey 08807, a citizen of the United States of America; and 
James Merl Clevenger, residing at 432 Little Brook Road, Glen 
Gardner, New Jersey 08826, a citizen of the United States of 
America. 
Prepared by: Karen G. Kaiser, Esq. 
Patent Department 
Ciba - Geigy Corp. 
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Background of the Invention 
This invention relates to cross-linked hydrophilic polymeric films, the process of 
making such films, and their use in applications where strength of the polymer 
article and high permeability to water are required simultaneously. In particular, 
these films are suitable for use as a carrier for biologically active agents, such as 
pharmaceuticals, both human and veterinary, insecticides, and fertilizers; as 
hydrophilic membranes for separation processes; as bandages for wound 
treatment; as body implants or as coatings for such implants; and as coatings on 
glass, metal , wood or ceramics. 
Such films, particularly when used as biological carriers, should not only be able 
to entrap the biological agent, but should also be biocompatible; that is, both 
mild and non-cytotoxic to living organisms. Additionally, they should be 
chemically and mechanically stable. 
Cross-linked polymeric films have been made. For example, U.S. Patent Nos. 
2,976,576 and 3,220,960 disclose cross-linked hydrophilic polymers which are 
produced by polymerizing a hydrophilic monomer in the presence of a cross-
linking agent; U.S. Patent No. 3,520,94 discloses hydrophilic cross-linked 
polymers which are produced by admixing a water-soluble polymerizable 
hydroxyalkyl monoester of a mono-olefinic monocarboxylic acid and a 
polymerizable diester of a mono-olefinic monocarboxylic acid in the presence of 
a linear polyamide; and U.S. Patent Nos. 4,192,827 and 4,277,582 disclose 
cross-linked polymers which are produced from a polymer of mono-olefinic 
monomers or copolymers of mono-olefinic monomers which is cross-linked with 
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a terminal diolefinic hydrophobic macromer. However, the use of monomers is 
disadvantageous in the pharmaceutical industry due to the potential cytotoxicity 
of unreacted monomers. 
Other cross-linked polymeric films have been made from polymers, thereby 
overcoming the problem of unreacted monomers. For example, WO 93/09176 
discloses cross-linking of polysaccharides, polycations and lipids with 
polymerizable acrylate in the presence of a radical initiator by using certain 
sources of energy; U.S. Patent No. 3,077,468 discloses the method of cross-
linking water-soluble hydroxyalkyl polysaccharide ethers by reacting them with 
an insolubilizing agent selected from unsaturated dibasic aliphatic acids and 
their anhydrides and the water-soluble derivatives of said acids and their 
anhydrides; and U.S. Patent No. 3,272,640 discloses cross-linking water-
soluble polymers by reacting them with a hydrophobic film former. 
Summarv of the Invention 
It is accordingly an object to the present invention to provide cross-linked, 
hydrophilic polymeric films which are suitable for use as a carrier for biologically 
active agents, such as pharmaceuticals, both human and veterinary, 
insecticides, and fertilizers; as hydrophilic membranes for separation processes; 
as bandages for wound treatment; as body implants or as coatings for such 
implants; and as coatings on glass, metal, wood or ceramics. 
It is another object of this invention to provide such a film which is essentially 
insoluble in aqueous and non-aqueous solutions. 
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It is yet another object of this invention to provide a cross-linked hydrophilic 
polymeric film which can be prepared without the use of organic solvents. 
It is still another object of this invention to provide a cross-linked hydrophilic 
polymeric film which is safe for in vivo usage. 
These, and other objects apparent to those skilled in the art from the following 
detailed description, are accomplished by the present invention which pertains 
to cross-linked hydrophilic polymeric films, the process of making such films, and 
their use. These films are produced by the application of an aqueous solution of 
a water-soluble polymer and a photosensitive or light degradable catalyst to a 
suitable substrate, optionally drying said solution, and exposing the resultant film 
to a suitably interacting energy source. 
Detailed Description of the Invention 
This invention pertains to cross-linked hydrophilic polymeric films, the process of 
making such films, and their use. These films are produced by the application of 
an aqueous solution of a water-soluble polymer and a photosensitive or light 
degradable catalyst to a suitable substrate, optionally drying said solution, and 
exposing the resultant film to a suitably interacting energy source. 
Appropriate polymers are those which are water-soluble and possess a structure 
which, in the presence of a suitable catalyst or cross-linking agent, may bond to 
additional molecules, thus yielding a macromolecule of said polymer which, due 
to its increased molecular weight, is no longer readily soluble in an aqueous 
medium. These polymers include, but are not limited to, water-soluble polyvinyl 
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alcohols, poly(hydroxyethyl methacrylates), and polysaccharides, particularly 
hydroxyalkyl polysaccharide ethers, more particu larly cellulose ethers such as 
hydroxyethyl cellulose and hydroxypropyl methylcellulose. Polymers which have 
low viscosities are preferred; those which have viscosities which approach that 
of water are most preferred. 
The amount of polymer used is that which can be solubilized in water and still 
remains free-flowing. A solution with a viscosity near that of water is preferred. 
Particularly, from about 1.0 to about 30% (w/w), more particularly from about 1.0 
to about 6.0% (w/w) of the polymer is used. 
Appropriate catalysts include those which are photosensitive or light degradable, 
such as azo dyes and riboflavin. The catalysts include, but are not limited to, 
riboflavin and its derivatives, Congo red, Evans blue, chlorazodin, ery1hrosine 
(FD&C Red #3), FD&C Red #40, tartrazine (FD&C Yellow #5), fast green FCF 
(FD&C Green #3), sunset yellow FCF (FD&C Yellow #6), brilliant blue FCF 
(FD&C Blue #1 ), and indigotine (FD&C Blue #2). In particular, the catalyst is a 
flavin . More particularly, the catalyst is riboflavin or a riboflavin derivative, 
preferably water soluble riboflavin derivatives, including, but not limited to, 
riboflavin-5'-phosphate or a salt thereof, riboflavin-5'-adenosine diphosphate, 6-
hydroxyriboflavin, 8-nor-8-hydroxyriboflavin, roseoflavin, 5-deazariboflavin, 8a-
(N 1-histidyl)flavin, 8a-(N3-histidyl)flavin, 8a-S-cysteinylflavin, 6-S-cysteinylflavin, 
lumiflavin, and lumichrome. Most particularly the catalyst is riboflavin-5'-
phosphate sodium. 
Typically 0.1 to 10% (w/w), more particularly from about 1.0 to about 4% (w/w) of 
the catalyst is used, based on the total weight of the solids (polymer plus 
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catalyst) in solution. Before forming the film, the solution of polymer plus 
catalyst may be deaerated so as to decrease the amount of air trapped within 
the final product. Deaeration may be accomplished by allowing the solution to 
stand, particularly in a darkened, refrigerated room, ie. overnight, or by 
conventional methods known in the art. Although it is not necessary, deaeration 
generally improves the quality of the resultant film. 
To form the film, the polymer is applied to a substrate. If the film is to be formed 
separately, as opposed to being coated onto an object, the substrate should be 
a smooth, non-reactive surface, ie. glass. Application may be by any 
conventional method known in the art. 
The film is preferably allowed to dry before exposure to the energy source. 
Although th is will occur at ambient temperatures, heat and or vacuum may be 
applied to decrease drying time. The film is preferably allowed to dry to a water 
content of no more than 30%, more narrowly to one of no more than 10%. 
However, as the film is hydrophilic, it is common for it to pick up water, thus 
rehydrating to some extent. 
The energy source used to cure the polymer may be any type of electromagnetic 
radiation, such as actinic light, x-rays, or gamma radiation. Light sources, 
particularly those within the ultraviolet or visible range, are preferred, particularly 
those with wavelengths of from approximately 200 to approximately 800 
nanometers, more particularly those with wavelengths of from approximately 300 
to approximately 700 nanometers. When the polymer is to be used as a carrier 
for a biologically active agent, particularly pharmaceuticals, it has been found 
that light within the visible range is most preferred because of the potential for 
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degradation of the active agent outside of this range. The wavelength most 
suited to use in any particular curing will depend upon the catalyst chosen. 
The film should be exposed to the energy source for such time as is necessary 
to achieve the desired amount of cross-linking of the polymer, particularly for 
such time as is necessary to ensure that the film is no longer freely soluble in an 
aqueous medium. The exposure time is dependent upon the intensity and type 
of energy source used as well as the type of polymer and thickness of the film. 
Sufficient exposure is generally indicated by a change in film color due to the 
catalyst. For example, the film turns from a bright yellow to a yellow-brown color 
when riboflavin or a derivative thereof is used as the catalyst. 
Surprisingly, the instant reaction will occur in the presence of oxygen unlike 
many others in which free radical scavenging inhibits the reaction. In addition, 
when the energy source used is light, the reaction is substantially temperature 
independent within the range of 0-100°C though ambient conditions are 
considered to be best. The reaction may proceed without organic solvents. 
Whenever organic solvents are used in a pharmaceutical process, measures 
need to be taken to protect the operators who produce the dosage forms and the 
environment from overexposure to the hazardous, often teratogenic and 
carcinogenic, materials. Additional precautions are necessary to protect 
equipment and facilities from harm. Further, despite all precautions, it is still 
likely for detectable levels of residual solvent to remain in the finished dosage 
form. Not only is the instant process advantageously safer, but the resultant film 
is safer in that it does not contain residual organic solvents. Thus, the present 
reaction, which may proceed without organic solvents, is advantageous, 
especially in the pharmaceutical industry. 
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Another safety advantage in the pharmaceutical industry is that since polymeric, 
not monomeric, materials are used, the cytotoxic potential of unreacted 
monomers is eliminated. Further, the film may be made with ingredients which 
are "generally regarded as safe" (GRAS) by the Food and Drug Administration. 
The cured polymer may be applied using any conventional coating technique 
including, but not limited to, spray coating, dip coating, and fluidized bed 
coating. The resultant film is substantially water insoluble and hydrophilic. 
Further, it tends to be insoluble in both acidic and alkaline solutions. The film is 
not appreciably elastic, but is flexible and continuous. 
The possible film thickness is dependent upon the light penetration. If thicker 
films are desired, however, multiple layers may be applied successively, each 
layer being cured before the next layer is deposited. This is especially useful in 
coating processes, for example coating of a pharmaceutical dosage form. 
The resultant film can be used, inter alia, as a carrier for biologically active 
agents, particularly pharmaceutically active agents. The term "pharmaceutically 
active agent," as used herein, refers to any composition of matter which will 
produce a pharmacological or biological response, including pharmaceuticals 
which are used to treat the body topically as well as systemically. Suitable 
mixtures of such active agents can be dispensed with equal facility as with single 
component systems. Furthermore, derivatives of these pharmaceutically active 
agents, eg. ethers, esters, amides, etc. , which are easily hydrolyzed within the 
body can be employed as can various forms of the active agents, eg. salts, 
acids, complexes, etc. 
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Pharmaceutically active agents useful in the present invention include, but are 
not limited to, proteins and peptides, antiasthmatics, antianginals, 
corticosteroids, 5-lipoxygenase inhibitors, antihypertensives, and leukotriene 84 
receptor antagonists. Proteins and peptides include, but are not limited to, 
transforming growth factors (TGF), immunoglobulin E (lgE) binding factors , 
interleukins, interferons (IFN), insulin-like growth factors (IGF), milk growth 
factors , anticoagulants, anabolics, analgesics, androgens, antibiotics, 
androgens, antidepressants, antidiabetics, anticonvulsants, antihistamines, 
antihypertensives, antiinfectives, antiparasistics, antiparkinson agents, 
antiphlogistics, antitussives, appetite depressants, bronchodilators, coronary 
dilators, corticoids, cytostatics, diuretics, hypnotics, neuroleptics, psycho-
analeptics, tranquilizers, uricosurics, vasodilators, and parathyroid hormones 
(PTH). Specific active agents include, but are not limited to IGF-1, PTH (1-34) 
and analogues thereof, TGF w TGF 131 • TGF l32• TGF l33• IF Na, hybrid IF Na, IFNy, 
hirudin, heparin, calcitonin, 5-aminosalicylic acid, CGS 23885, CGS 25019C, 
CGS 26529, Zileuton, ONO-LB 457, beclomethasone dipropionate, 
betamethasone-17-valerate, prednisolone metasulfobenzoate, tixocortol 
pivalate, budesonide, fluticasone, metoprolol fumarate, metoprolol tartrate, 
tetrahydroaminoacridine (THA), galanthamine, theophylline, ursodiol, 
clomipramine hydrochloride, terbutaline sulfate, aminoglutethimide, 
deferoxamine mesylate, estradiol, isoniazid, metyrapone, methandrostenolone, 
acetylsalicylic acid, phenylbutazone, methadone, methyltestosterone, 
imipramine, maprotiline, phenformin, carbamazepine, tripelennamine, 
hydralazine, trimethoprim, nifurtimox, levodopa, naproxen, benzonatate, 
mazindol , fenoterol , fenalcomine, dexamethasone, floxuridine, 
hydrochlorothizide, glutethimide, reserpine, methylphenidate, diazepam, 
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sulfinpyrazone, isoproterenol, and rifampin. 
As used herein, the active agents CGS 23885, 25019C, CGS 26529, Zileuton, 
ONO-LB 457 are defined as follows: CGS 23885 refers to N-hydroxy-N-((6-
phenoxy-2H-1-benzopyran-3-yl)methyl)- urea; CGS 25019C refers to 4-[5-[4-
( aminoiminomethyl)phenoxy] pentoxy]-3-methoxy-N, N-bis( 1-
methylethyl)benzamide (Z)-2-butenedioate; CGS 26529 refers to N-[2-[[2-[[4-{4-
fluorophenyl)phenyl]methyl]-1 ,2,3, 4-tetrahydro- 1-oxo-6-isoquinolinyl]oxy]ethyl]-
N-hydroxyurea; Zileuton refers to 1-(1-benzo[b ]thien-2-ylethyl)-1-hydroxyurea; 
ONO-LB 457 refers to 5-[2-(2-carboxyethyl)-3-{6-(para-methoxyphenyl)-5E-
hexenyl} oxyphenoxy] valeric acid. 
Incorporation of the biologically active agent into the polymeric film may be 
accomplished by dissolution or dispersion into the polymer solution prior to 
curing or by diffusion into the finished article after cross-linking has occurred. In 
the alternative, the polymeric film can be hydrated in a solution of the active 
agent to be delivered and the solvent is then evaporated, leaving the agent 
within the film. 
The biologically active agent may also be incorporated by techniques known in 
the art, for example microcapsules could be formulated by air-jet droplet 
generation, co-axial extrusion, or by emulsification. Incorporation may also be 
accomplished by coating the agent, either alone or admixed with acceptable 
excipients, using coating techniques known in the art, for example spray-coating 
or fluidized bed coating. 
A pharmaceutical dosage form, such as a tablet or capsule, may alternatively be 
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coated by admixing the polymer and catalyst, compression coating said mixture 
onto the pharmaceutical dosage form, and then exposing the compression 
coated form to the energy source. In this manner, the film is formed without any 
solvents. Techniques known in the art may be used to optimize this process; for 
example, the polymer/catalyst mixture may be ground to an appropriate particle 
size or acceptable tabletting agents may be added to the mixture. 
The amount of the biologically active agent incorporated within the film may vary 
widely depending upon the particular agent, the desired therapeutic effect, and 
the time span of release. 
As a carrier, the film may be used as a semi-permeable membrane for controlled 
release delivery systems. The film may be used to coat products for controlled 
sustained release of their contents as is or the coated product may be further 
outfitted with an orifice for release of active agent. In this latter embodiment, the 
coated product functions in a manner similar to those utilizing the oral osmotic 
technology known under the Alza tradename OROS/. This product permits 
passage of water and certain dissolved materials, but retains others, thus 
allowing active agent to be emitted at a controlled rate. The films of this 
invention however differ from the typical semipermeable membrane used in an 
OROS-type system in that a release orifice is optional, not necessary. 
An additional advantage is that these polymeric films are easily removable 
before cross-linking as the polymer will readily form a viscous gel upon exposure 
to humidified environments. The gel-like film can then be easily removed by 
mechanical intervention. This is especially important in the field of 
pharmaceuticals as the film can be separated from the active agent after the 
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delivery device has been made. This separation allows for recovery of 
expensive pharmaceutical active agents. 
Examples 
Example 1 -
2% (w/w) Hydroxyethylcellulose with a viscosity averaged molecular weight of 
720,000 and 0.031 % (wlw based on total solids) riboflavin-5'-phosphate are 
dissolved in distilled water. The resultant solution is allowed to deaerate in a 
dark refrigerator overnight. The deaerated solution is poured onto a glass plate 
and spread to a thickness of 12 mils (0.305 mm) and subsequently dried in a 
conventional oven at 50°C to a moisture content of less than 10%. The film is 
then exposed to a visible light source rated at 600 footcandles (Hotpack 
environmental cabinet) for twenty-four hours. The resultant film is greater than 
90% insoluble in water at ambient conditions. 
Example 2 -
Three grams of hydroxyethylcellulose with a viscosity averaged molecular weight 
of 90,000 and a degree of substitution of 2.5 (ie. Natrosol 250L) and 60 mg of 
FD&C Blue #2 are dissolved in 100 ml of distilled water. The resultant solution 
is poured onto glass plates and spread to a thickness of 12 mils (0.305 mm) and 
subsequently dried in a conventional oven at 50°C to a moisture content of less 
than 10%. The film is then exposed to a high intensity ultraviolet lightsource 
(Mercury "H" bulb, 600 Watts/inch) for approximately 30 seconds. The resultant 
film is crosslinked and is insoluble, but swellable in water. 
Example 3-
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The process of Example 2 is repeated with the exception that the catalyst used 
is riboflavin-5'-phosphate. 
Example 4-
2% (w/w) Hydroxyethylcellulose with a viscosity averaged molecular weight of 
720,000 and a degree of substitution of 2.5 (grade M) and 2% (w/w based on 
total solids) riboflavin-5'-phosphate are dissolved in distilled water using a 
homogenizer. The resultant solution is deaerated overnight in a dark 
refrigerator. The deaerated solution is poured onto a glass plate which had 
been preheated to 60°C and spread to a wet thickness of 0.040 inches 
(approximately 1.0 mm). The film is subsequently dried in a conventional oven 
at 60°C overnight. The film is then exposed to a high intensity ultraviolet 
lightsource (Mercury "H" bulb, 600 Watts/inch) for 30 seconds. The resultant 
film is approximately 75% insoluble in water at ambient conditions. 
Example 5 -
The process of Example 4 is repeated with the exception that the energy source 
used is visible light rated at 600 footcandles (Hotpack environmental cabinet) 
and exposure is for twenty-four hours. The resultant film is in excess of 80% 
insoluble in water at ambient conditions. 
Example 6 -
1.5% (w/w) Hydroxyethylcellulose which has a viscosity averaged molecular 
weight of 720,000 and a degree of substitution of 2.5 (Natrosol 250M) and 
0.031 % (w/w) riboflavin-5'-phosphate are dissolved in distilled water using a 
conventional mixer. The solution is deaerated overnight in a darkened 
refrigerator. 
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10.5 Kg of this solution is used to coat 1.25 Kg of 75 mg tablets containing 
dextromethorphan using conventional spraying in a pharmaceutical coating pan. 
The resultant coated tablets each contain 6.1 mg coating. 
Example 7 -
The process of Example 6 is repeated except that the coated tablets are then 
exposed to ultraviolet light (Mercury "H" bulb, 600 Watts/inch) on all sides for 
approximately 60 seconds. 
Example 8 -
A standard USP dissolution test in water USP is used to compare the coated 
tablets of Examples 6 and 7. Exposure of the coated tablets to ultraviolet light 
significantly decreased the dissolution rate. Eighty percent release occurred at 
30 minutes for the tablets of Example 6, but did not occur until 150 minutes for 
the tablets of Example 7, a five-fold difference. 
Example 9-
The process of Example 7 is repeated except that the coating weight of each 
tablet is 7.9 mg and the energy source is visible light rated at 600 footcandles 
(Hotpack environmental cabinet) with exposure for 7 days. 
Example 10-
The process of Example 9 is repeated except that each tablet is pierced with a 
single hole measuring 0.025 inches (approximately 0.635 mm) in diameter to 
form a release orifice. 
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Example 11 -
A standard USP dissolution test in water USP is used to compare the coated 
tablets of Examples 9 and 10. Eighty percent release occurred at 3 hours for the 
tablets of Example 9, but did not occur until 4.1 hours for the tablets of Example 
10. 
Example 12 -
1.5% (w/w) Hydroxyethylcellulose which has a viscosity averaged molecular 
weight of 720,000 and a degree of substitution of 2.5 (Natrosol 250M) and 
0.031 % (w/w) riboflavin-5'-phosphate are dissolved in distilled water using a 
conventional mixer. The solution is deaerated overnight in a darkened 
refrigerator. 10.5 Kg of this solution is used to coat 1.25 Kg of 215 mg tablets 
containing metoprolol fumarate using conventional spraying in a pharmaceutical 
coating pan. The resultant coated tablets each contain 18 mg coating. 
Example 13 -
The process of Example 12 is repeated except the coated tablets were exposed 
to 600 foot-candles of visible light for 6 days. 
Example 14 -
A standard USP dissolution test in water USP is used to compare the coated 
tablets of Examples 12 and 13. Eighty percent release occurred at 3 hours for 
the tablets of Example 13, but did not occur until 6 hours for the tablets of 
Example 12. 
The above description is for the purpose of teaching the person of ordinary skill 
in the art how to practice the present invention and it is not intended to detail all 
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those obvious modifications and variations of it which will become apparent to 
the skilled worker upon reading the description. It is intended, however, that all 
such obvious modifications and variations be included within the scope of the 
present invention and by the following claims. 
What is claimed is: 
1. A method of preparing a hydrophilic cross-linked polymer which comprises 
solubil izing a water-soluble polymer containing an effective amount of a 
photosensitive or light degradable catalyst and exposing the solution to an 
electromagnetic energy source. 
2. The method of claim 1, wherein the water-soluble polymer is selected from 
the group consisting of the water-soluble polysaccharides, polyvinyl 
alcohols, and poly(hydroxyethyl methacrylates). 
3. The method of claim 2, wherein the polymer is selected from the group 
consisting of hydroxyethyl cellulose and hydroxypropyl methylcellulose. 
4. The method of claim 1, wherein the amount of polymer used is from about 
1.0% to about 30% by weight of the solution. 
5. The method of claim 1, wherein the catalyst is selected from the group 
consisting of flavins, Congo red, Evans blue, chlorazodin, erythrosine 
(FD&C Red #3), FD&C Red #40, tartrazine (FD&C Yellow #5), fast green 
FCF (FD&C Green #3), sunset yellow FCF (FD&C Yellow #6), brilliant blue 
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FCF (FD&C Blue #1 ), and indigotine (FD&C Blue #2). 
6. The method of claim 5, wherein the flavinoid catalyst is selected from the 
group consisting of riboflavin and riboflavin derivatives. 
7. The method of claim 5, wherein the flavinoid catalyst is riboflavin-5'-
phosphate or a salt thereof. 
8. The method of claim 1, wherein the amount of catalyst used is from about 
0.1 to about 10% of the combined weight of the polymer and catalyst. 
9. The method of claim 1, wherein the energy source is light. 
10. The method of claim 9, wherein the light is visible or ultraviolet. 
11 . The method of claim 10, wherein the light is in the range of from 
approximately 400 to approximately 700 nanometers. 
12. The method of claim 1, which further comprises drying the solution before 
exposing it to the energy source. 
13. A hydrophil ic crosslinked polymeric film prepared by the method of claim 1. 
14. A pharmaceutical delivery system comprising the film of claim 13 and at 
least one pharmaceutically acceptable active agent. 
15. A method of coating a pharmaceutical dosage form with a hydrophilic 
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cross-linked polymer which comprises: admixing a water-soluble polymer 
and an effective amount of a photosensitive or light degradable catalyst to 
form a mixture; compression coating said mixture over a pharmaceutical 
dosage form; and exposing the coated dosage form to an electromagnetic 
energy source. 
Abstract 
This invention pertains to cross-linked hydrophilic polymeric films, the process of 
making such films, and their use. The films of this invention are produced by 
solubilizing a water-soluble polymer with a photosensitive or light degradable 
catalyst, optionally drying said solution, and exposing the solution to an energy 
source, particularly light. These films are suitable for use as a carrier for 
biologically active agents, such as pharmaceuticals, both human and veterinary, 
insecticides, and fertilizers ; as hydrophilic membranes for separation processes; 
as bandages for wound treatment; as body implants or as coatings for such 
implants; and as coatings on glass, metal, wood or ceramics. 
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